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The central nervous system is a web of neuronal communication, mediated through excitatory and 
inhibitory signals. These signals are mediated in part by the amino acid neurotransmitters 
glutamate, GABA and glycine, which are ligands for specific ligand-gated ion channels. While 
direct activation or inactivation of ligand-gated ion channels can cause marked and sometimes 
detrimental changes in the nervous system, allosteric modulators of these channels can produce 
more subtle and specific changes. Despite the clinical potential of allosteric modulators, the 
molecular mechanisms of their action at ligand-gated ion channels are poorly understood. This 
dissertation covers several aspects of allosteric modulation: elucidating the molecular mechanism 
of known exogenous modulators, identifying endogenous compounds as modulators, and using a 
drug discovery technique to find novel modulators. The first chapter details how ketone bodies are 
endogenous allosteric modulators of NMDA, GABAA and glycine receptor function, and that this 
action of ketone bodies may underlie therapeutic benefits. Next, I characterize how 
benzodiazepines, acting as positive allosteric modulators of the GABAA receptor, produce a 
molecular rearrangement in the GABAA receptor resulting in an enhancement in receptor function. 
This involves an interaction between charged residues at the interface of adjacent subunits of the 
GABAA receptor. Finally, I utilize phage display technology to identify peptides capable of 
   vii 
allosteric modulation of the GABAA receptor, providing evidence that this technique can be used 
to identify new compounds for a large range of indications. 
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CHAPTER 1. INTRODUCTION 
1.1 Amino Acid Transmitters: Glutamate, GABA and Glycine 
Amino acid transmitters are amino acids capable of participating in synaptic transmission, 
and can be divided based on their excitatory or inhibitory properties. Glutamate, gamma-
aminobutyric acid (GABA) and glycine are the most prevalent amino acid transmitters, with 
glutamate acting in an excitatory manner and GABA and glycine acting in an inhibitory manner 
via their respective receptors. These amino acids are natural metabolites produced by a variety of 
pathways. 
 
Glycine is produced from another amino acid, serine, by the enzyme serine 
hydroxymethyltransferase while glutamate and GABA come indirectly from the breakdown of 
glucose via the Krebs cycle.  -ketoglutarate, a Krebs cycle intermediate, is converted to glutamate 
via alanine transaminase. Glutamate can also be synthesized from another amino acid, glutamine, 
found in astrocytes at high concentrations. Astrocytes take up extracellular glutamate via 
excitatory amino acid transporters, and convert glutamate to glutamine using glutamate synthase. 
Glutamine can exit astrocytes and enter neurons (both via glutamine transporters), where 
glutaminase can re-convert glutamine to glutamate. Glutamic acid decarboxylase converts 
glutamate to GABA. 
 
After synthesis, glutamate, GABA and glycine are packaged into distinct synaptic vesicles, 
sometimes within the same neuron (Todd et al., 1996; Somogyi and Llewellyn-Smith, 2001; 
Gundersen, 2008; Shabel et al., 2014). Depolarization of a presynaptic neuron triggers calcium ion 
influx through calcium channels which in turn results in fusion of the synaptic vesicle with the 
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presynaptic membrane, releasing the synaptic vesicle contents into the extracellular space where 
they can then act on their respective presynaptic and/or postsynaptic receptors. 
 
1.2 Neurotransmitter Actions on a Receptor 
The binding of a neurotransmitter (agonist) to its receptor triggers a conformational change 
in the receptor which results in a subsequent event, such as the opening of an ion-conducting pore 
or G-protein activation. The ability of an agonist to bind to its receptor is determined by the affinity 
of the agonist for that receptor. The ability of the agonist, after binding, to produce subsequent 
conformational changes leading to receptor activation, is determined by the agonist's efficacy for 
the receptor. These separate affinity and efficacy steps of drug action at a receptor were first 
described by del Castillo and Katz in 1957. (Figure 1). While the binding step can be maximized 
(as is seen in 100% binding site occupation in the case of irreversibly-binding ligands), efficacy 
has no upward limit since it is a ratio of two rate constants that describe the transitions between 
closed and open states of ion channels; the term full agonist is sometimes used to describe the most 
efficacious compound known at that time. 
 
 
 
  
 3 
Figure 1. Simplified del Castillo-Katz mechanism of ion channel receptor activation.  
A ligand (in orange) binds to an unopened receptor (left, black ovals). The ligand binds to the 
unopened receptor with a certain affinity for its binding site on the receptor (middle). Depending 
on the ligands efficacy, the ligand can produce opening of the ion channel and allow ion influx 
(right).   The rate constant k+1 describes the rate of agonist binding and is described in units of  
s-1M-1, while k-1 is the rate of agonist unbinding, in units of s-1. The ratio of k-1/k+1 yields binding 
affinity (in molar units).  The transition rate between the receptor-bound closed and open channel 
states of the receptor is  (expressed in units of s-1) while the converse rate is  (also in units of  
s-1) and / yields efficacy, which is unitless.  
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Prolonged activation of the receptor results in receptor desensitization, a refractory period 
in which the channel remains closed despite agonist being bound to the receptor (Jones and 
Westbrook, 1995; Jones and Westbrook, 1996).  Additionally, there may be a separate step 
involved between agonist binding and receptor activation, known as a pre-activated flip state, at 
least in the cys-loop glycine and GABAA receptors. ‘Flipping’ the receptor from its pre-activated 
state results in channel activation (Burzomato et al., 2004; Lape et al., 2008; Mukhtasimova et al., 
2009). 
Allosteric modulators are molecules that act on a receptor through a site that is separate 
from the ligand binding site and are unable to activate the receptor in the absence of a ligand. 
Allosteric modulators, such as a variety of benzodiazepines that act at GABAA receptors, vary in 
their affinities for a receptor’s modulatory site and exert their actions by indirectly producing a 
change in the affinity or efficacy of a ligand for its receptor. While modulators are often incorrectly 
described as having efficacy at their receptor, they have no efficacy as they are unable to activate 
the receptor in the absence of a receptor agonist. Receptor antagonists block agonist action by 
either directly competing with an agonist for its site, as is the case for a competitive antagonist, or 
through an action at a separate site. 
 
1.3 Ionotropic Glutamate Receptors  
Ionotropic glutamate receptors are excitatory neurotransmitter receptors that exist both pre-
synaptically and post-synaptically. Activation of these receptors by a ligand results in the opening 
of a central cation-conducting pore, allowing for depolarization of the cell to occur. Ionotropic 
glutamate receptors can be split into two subtypes: N-methyl-D-aspartate (NMDA) and non-
NMDA receptors. The non-NMDA receptor group consists of α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid (AMPA) and kainate receptors. While these receptors are all activated by 
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glutamate, they can be differentiated pharmacologically by synthetic compounds such as AMPA, 
NMDA and kainate.  
Ionotropic glutamate receptors are responsible for excitatory neurotransmission in the 
central nervous system, with non-NMDA receptors mediating a faster activation/deactivation 
component of excitatory transmission than NMDA receptors (Umemiya et al., 1999). These 
receptors are comprised of four subunits, with each subunit made up of three transmembrane 
domains (TMD1, TMD3 and TMD4) and one re-entrant loop in place of TMD2 (Laube et al., 
1998; Rosenmund et al., 1998). The re-entrant loop forms the pore while the ligand binding domain 
is formed by the N-terminal of the receptor and the extracellular loop between TMD3 and TMD4 
(Kuner et al., 2001; Stern-Bach et al., 1994).   
 
1.3.1 NON-NMDA RECEPTORS 
AMPA receptors are comprised of four different subunits (GluR1, GluR2, GluR3 and 
GluR4) in various combinations, while kainate receptors can be comprised of five different 
subunits (GluR5, GluR6, GluR7, KA1 and KA2). Each subunit comprising AMPA and kainate 
receptors is large, with some subunits/splice variants up to almost a thousand amino acids long. 
Electron microscopy and X-ray crystallography have revealed that these receptors assemble as 
dimers of dimers, meaning two different subtypes assemble with another pair in order to form a 
four-subunit receptor (Safferling et al., 2001; Sobolevsky et al., 2009). The receptor is thought to 
be arranged so that like-subunits are diagonally opposed. While homomeric receptors do exist 
(meaning four identical subunits), AMPA and kainate receptors are thought to mostly exist as 
heterodimers.  
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AMPA and kainate receptors conduct Na+ ions through their central pores once activated. 
However, if the AMPA receptor lacks a GluR2 subunit (which is not the case most of the time), 
that AMPA receptor is also permeable to Ca2+ ions (Sommer et al., 1991; Burnashev et al., 1996). 
AMPA GluR2 subunits undergo post-transcriptional Q/R RNA editing, where an uncharged 
glutamine (Q) at position 586 (part of the re-entrant loop) is replaced by a positively charged 
arginine (R). This renders the GluR2-containing AMPA receptor impermeable to Ca2+. The kainate 
receptor subunits GluR5 and GluR6 also undergo RNA editing at this position, and thus kainate 
receptors containing these subunits are also not Ca2+ permeable. AMPA and kainate receptors that 
are permeable to Ca2+ are blocked by endogenous polyamines (eg. spermine) and display an 
inwardly rectifying current/voltage relationship, meaning that little current flows through these 
receptors at positive membrane potentials (Bowie and Mayer, 1995). 
 
1.3.2 NMDA RECEPTORS 
NMDA receptors, like AMPA receptors, are composed of four subunits, each with three 
transmembrane spanning domains (TMD1, 3 and 4) and with a re-entrant loop in place of TMD2, 
that lines the channel pore. Seven NMDA receptor subunits have been identified; NR1, NR2A, 
NR2B, NR2C, NR2D, NR3A and NR3B. The NR1 subunit is encoded by a single gene, but post-
translational modifications can result in eight functional isoforms of this subunit. The NR2 family 
(NR2A, 2B, 2C and 2D) are encoded by four separate genes, and all but NR2A have splice variants. 
The NR3 family (A and B) has been studied less and consists of two gene members. The NR3 
subunits may act as modulatory subunits in some brain regions and appear less frequently than the 
NR1 and NR2 subunits. The number of possible subunit combinations to form a receptor results 
in considerable NMDA receptor diversity. mRNA for NR1 subunits is expressed ubiquitously 
throughout the CNS; however, NR2 subunit expression is more varied by subtype, depending on 
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brain region and developmental stage (Laurie and Seeburg, 1994; Cull-Candy and Leszkiewicz, 
2004). 
 
NMDA receptors do not exist as homomers, as they require two NR1 subunits and at least 
one type of NR2 subunit (Monyer et al., 1992). NR1 subunits can combine with NR3 subunits in 
the absence of NR2, but these receptors are not responsive to glutamate, only glycine (Chatterton 
et al., 2002). Like the non-NMDA receptors, these receptors form heterotetramers where like-
subunits are arranged diagonally opposed to one another (Salussolia et al., 2011; Riou et al., 2012; 
Karakas and Furukawa, 2014).  
 
1.3.2.1 NMDA Receptor Agonist Binding and Activation 
NMDA receptor activation slightly differs to that of non-NMDA receptors. Like non-
NMDA receptors, NMDA receptors have an agonist binding domain formed from a clam-shell 
pocket created by the extracellular N-terminus and the loop between TMD3 and TMD4 (Stern-
Bach et al., 1994; Furukawa and Gouaux, 2003). After agonist binding, the two domains 
contributing to the binding pocket close and induce a conformational change in the transmembrane 
domains of the receptor (Armstrong and Gouaux, 2000). While four agonists can bind to one non-
NMDA receptor, this is not the case for NMDA receptors. The pocket created by NR2 subunits 
can bind glutamate, however the pocket created by NR1 subunits is too small for glutamate to bind 
(Laube et al., 1997). Instead, the pocket created by NR1 subunits (or NR3 subunits) is for glycine, 
a co-agonist of the NMDA receptor (Johnson and Ascher, 1987; Tikhonova et al., 2002) (Figure 
2). D-serine is also capable of activating the glycine co-agonist site (Miller et al., 2004). NMDA 
receptors require both glutamate and glycine binding site occupation to open, explaining why 
homodimers of the NMDA receptor do not exist. While non-NMDA receptors can open with just 
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one glutamate molecule bound to one subunit, NMDA receptors have two agonist sites and two 
co-agonist sites and require that the co-agonist site is occupied before the channel can open 
(Clements and Westbrook, 1991; Smith and Howe, 2000). 
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Figure 2. Illustration of the NMDA receptor.  
(A) One ionotropic glutamate receptor subunit is comprised of three transmembrane domains and 
a re-entrant loop in place of transmembrane domain two. The ligand binding domain is formed by 
the N-terminal domain and the extracellular loop between transmembrane domains three and four. 
The plasma membrane is depicted in beige. Four subunits form a functional NMDA receptor as 
seen in (B), with NR1 subunits containing the co-agonist glycine binding site (in green) and the 
NR2 subunit containing the glutamate binding site (in pink). 
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In addition to the requirement of a co-agonist, NMDA receptors also have a voltage-
dependent block by Mg2+ (Ruppersberg et al., 1994). After the cell is depolarized, the Mg2+ block 
is relieved and the channel can conduct ions through its pore. NMDA receptors are permeable to 
calcium ions, as they have an asparagine residue (N598) in a position homologous to that of the 
Q/R post transcriptional editing site in non-NMDA receptors (Burnashev et al., 1992). 
Mutagenesis of N598 to a charged glutamine residue in the NR1 subunit renders the NMDA 
receptor less permeable to Ca2+ and slightly reduces the Mg2+ block. Conversely, mutation of N598 
to a charged glutamine residue in the NR2 subunit renders the NMDA receptor much less sensitive 
to Mg2+ while having almost no effect on Ca2+ permeability (Sakurada et al., 1993). The ability of 
NMDA receptor to conduct Ca2+ ions is thought to play a major role in synaptic plasticity (Malenka 
and Nicoll, 1993). 
 
1.3.2.2 Zinc Modulation of the NMDA Receptor 
Zinc is present throughout the central nervous system, with synaptic concentrations in the 
brain thought to reach as high as 100M (Assaf and Chung, 1984; Frederickson, 1989). Zinc can 
accumulate in neurons in presynaptic vesicles via a zinc transporter and is often co-localized in 
brain regions with the NMDA receptor (Palmiter et al., 1996; Sindreu et al., 2003). While high 
concentrations of zinc can act similarly to Mg2+ by voltage-dependently blocking the channel pore 
(Kawajiri and Dingledine, 1993; Williams, 1996), it is thought to have a second site of action in 
the extracellular N-terminal domain region of the receptor (Choi and Lipton 1999; Fayyazuddin et 
al., 2000; Low et al., 2000).  Binding of low concentrations of zinc to residues in the N-terminal 
domain of the NR2 subunit is thought to allosterically stabilize the closed state of the NMDA 
channel by decreasing both the probability and duration of channel opening (Erreger and Traynelis, 
2008). The NR1 subunit N-terminal domain also appears to play a role, suggesting that zinc might 
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bind at the subunit interface between NR1 and NR2, as deletion of the NR1 N-terminal domain 
also eliminates zinc inhibition (Madry et al., 2007). Zinc binding to the N-terminal domain may 
also influence proton sensitivity of the receptor. Protons themselves act as allosteric inhibitors of 
the NMDA receptor, and the binding of zinc enhances the sensitivity of the receptor to proton 
inhibition (Choi and Lipton, 1999). This has been supported with single channel recording data 
showing changes in the protonation of the channels in the presence of zinc (Erreger and Traynelis, 
2008). Mutagenic studies suggest that the structural rearrangement of the channel that occurs after 
zinc binding separates the interface between NR1 and NR2 subunits and allows proton binding to 
occur (Gielen et al., 2008). There are subunit differences amongst this voltage-independent 
modulation by zinc, with a higher sensitivity to zinc inhibition exhibited by NR2A-containing 
receptors (nanomolar) than NR2B-containing receptors (micromolar) (Paoletti et al., 1997; 
Rachline et al., 2005).  
 
1.3.2.3 Ethanol Modulation of the NMDA Receptor 
Concentrations of alcohol obtained in humans after consuming alcohol (~20-50 mM) are 
capable of inhibiting NMDA receptor function, as seen in brain slices and in heterologous 
expression systems (Lovinger et al., 1989; Lovinger et al., 1990; Chu et al., 1995; Wright et al., 
1996; Xu and Woodward, 2006). Interestingly, the extent of inhibition produced by ethanol at 
NMDA receptors decreases quickly after a short period of time, an effect observed in vitro and in 
vivo and known as acute tolerance (Grover et al., 1994; Lin et al., 2003). At the single channel 
level, it appears that ethanol decreases the frequency of channel opening and the mean open time 
of the receptor (Wright et al., 1996). This effect of alcohol may be brought about by ethanol 
competing (directly or indirectly) with glycine at the NMDA receptor; however, other studies 
suggest that this is not the case (Rabe and Tabakoff, 1990; Woodward et al., 1991; Dildy-Mayfield 
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and Leslie, 1991; Peoples and Weight, 1992; Buller et al., 1995; Mirshashi and Woodward, 1995; 
Cebers et al., 1996). An amino acid (phenylalanine 639) in the TMD3 of the NR1 subunit confers 
sensitivity to ethanol, with mutation of this residue to alanine resulting in a decrease in receptor 
sensitivity to ethanol. Additionally, mutating specific residues in the NR1 subunit TMD4 enhances 
the receptor's sensitivity to ethanol (Ronald et al., 2001; Smothers and Woodward, 2006). Amino 
acids in TMD3 and TMD4 in the NR2A subunit may also play a role in conferring ethanol 
sensitivity (Ren et al., 2003; Honse et al., 2004; Ren et al., 2007). In contrast, the NR3 subunit is 
not thought to contribute towards the ethanol sensitivity of NMDA receptors (Smothers and 
Woodward, 2003).  
 
1.4 Cys-Loop Receptors: GABAA and Glycine Receptors 
GABAA and glycine receptors, as well as nicotinic acetylcholine and serotonergic 5-HT3A 
receptors, belong to the superfamily of cys-loop receptors. Cys-loop receptors all have thirteen 
amino acids in their N-terminal domains, flanked by a cysteine on either side, which form a 
disulfide bond, creating a conserved ‘loop’ of amino acids. Insight into the structure of these 
receptors has come from electron microscopy of the Torpedo nicotinic acetylcholine receptor and 
through similarities to existing crystal structures of the acetylcholine binding protein, Gloeobacter 
ligand-gated ion channel (GLIC), Erwinia ligand-gated ion channel (ELIC) and glutamate-gated 
ion channel (GluCl) (Unwin, 1995; Brejc et al., 2001; Hilf and Dutzler, 2008; Bocquet et al., 2009; 
Hibbs and Gouaux, 2011). Recently, cryogenic electron microscopy solved the structure of the 
GABAA receptor (Zhu et al., 2018).  Cys-loop receptors are comprised of five subunits, which 
form around a central anion or cation conducting pore. Each subunit has four transmembrane 
domains (TMD1-4), with a large N-terminal (containing the cys-loop), a large intracellular loop 
between TMD3 and TMD4, and a short C-terminal. The large N-terminal domain is where ligands 
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bind, and this occurs at the interface of two subunits. TMD2 primarily forms the ion-conducting 
pore of the channel, while the large intracellular loop is thought to be important for various receptor 
properties, such as receptor trafficking and post-translational modifications (Langlhofer and 
Villmann, 2016). The GABAA and glycine receptors have an anion-conducting pore, while 
nicotinic acetylcholine and serotonergic 5-HT3A receptors contain a cation-conducting pore. 
 
1.4.1 GABAA RECEPTORS 
GABAA receptors, like all cys-loop receptors, are comprised of five subunits (Figure 3). 
To date, 19 subunits have been identified: six alpha (1-6), three beta (1-3), three gamma (1-3), 
three pi (1-3) one epsilon, one omega, one delta and one pi subunit, from 16 different genes. While 
this would allow for enormous receptor diversity, it is estimated that under 20 combinations exist 
in the central nervous system (Enna, 2007). The most prevalent combination of GABAA receptor 
subunits appears to be the  receptor, containing 2 , 2 2 and 1 2 subunit(s). GABAA 
receptors are expressed throughout the brain, both pre- and post-synaptically, and are thought to 
be the main players in regulating inhibitory transmission. Immunohistological studies in the mouse 
brain suggest that  receptors are the second most abundant type of receptor but are more 
localized to certain areas compared to the  receptor, including the hippocampus, striatum, 
olfactory bulb and the amygdala (Nusser et al., 1996; Fritschy et al., 1998; Sassoe-Pogentto et al., 
2000). 3 containing receptors are also regionally restricted to specific brain regions, including the 
subthalamic nucleus, paraventricular nucleus, amygdala, raphe nuclei and the basal forebrain (Gao 
et al., 1993; Heldt and Ressler, 2007).  Receptors containing    and  subunits represent 
less than 10% of all GABAA receptors, are mostly extra-synaptic, and are responsible for slow 
tonic inhibition. The rho receptors exist as homomers or heteromers (of various  subunit 
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combinations) and are found in low levels throughout the central nervous system, but at high levels 
in the retina (Albecht et al., 1997; Koulen et al, 1998; Enz et al., 1999).  
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Figure 3. Illustration of the GABAA receptor.  
(A) Each GABAA receptor subunit is comprised of four transmembrane domains, a large N-
terminus which forms the agonist binding site, and a large intracellular loop between 
transmembrane domains three and four. The beige box represents the plasma membrane. Five 
subunits form a functional receptor, as seen in (B). The  GABAA receptor contains two GABA 
binding sites (pink ovals), one at each --+ interface.  
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During development GABAA receptors, as well as glycine receptors, can produce 
depolarization of the cell upon receptor activation. This is because the driving force of Cl- is 
reversed; after channel activation Cl- flows out of the cell rather than into the cell, as is seen in 
adults. This conversion of GABAA and glycine receptors from having excitatory to inhibitory 
actions is thought to be due to an increase in expression of the K+/Cl- KCC2 transporter during 
development (Rivera et al., 1999; Hubner et al., 2001). 
 
The GABAA receptor agonist binding site is at the --+ interface, explaining the need for 
both  and  subunits to form a functional receptor (GABAA rho receptors are the only exception) 
(Smith and Olsen, 1995). Tyrosine 97 and leucine 99 are thought to line the GABA binding site 
on the  subunit side, and leucine 99 of the  subunit may play a role in coupling GABA site 
agonist binding to channel opening (Boileau et al., 2002; Laha and Tran 2012). Upon activation 
by its ligand (e.g. GABA), GABAA receptors undergo a conformational change which results in 
channel opening, allowing Cl- to flow into the cell, ultimately resulting in cell hyperpolarization. 
It is unclear exactly how receptor binding triggers channel opening, but the conformational wave 
that occurs during this process may involve a series of electrostatic interactions between charged 
amino acids, which are broken or formed after agonist binding. Several studies have implicated 
electrostatic interactions within or between the  and  subunits before or after GABA binding. In 
the N-terminal region, the positively-charged arginine 120 of the 1 subunit may form an 
interaction with the negatively-charged aspartic acid 153 of the 2 subunit after GABA binds (Laha 
and Wagner, 2011). An electrostatic interaction between lysine 279, found in the 1 linker region 
between TMD2 and TMD3, with either aspartic acids 149 or 57, both found in the 1 N-terminal 
region, may be key to coupling agonist binding to channel opening (Kash et al., 2003). Another 
study found that glutamic acid 153 and lysine 196 in the N-terminal within the same 2 subunit 
interact to stabilize the open state of the channel (Venkatachalan and Czajkowski, 2008). The 
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involvement of electrostatic interactions in the coupling of agonist binding to channel gating is not 
unique for GABAA receptors, as similar electrostatic interactions have also been implicated in 
other cys-loop receptors (Mukhtasimova et al., 2005; Todorovic et al., 2010).  
 
1.4.1.1 Benzodiazepine Modulation of the GABAA Receptor 
Benzodiazepines have been widely prescribed since the 1960s. Drugs belonging to this 
class have the structure of a benzene ring fused with a diazepine ring, and include Valium® 
(diazepam) and Xanax® (alprazolam). These compounds are used therapeutically for their anti-
insomnia, anxiolytic and anti-convulsant properties. Unfortunately, tolerance to this class of 
compounds develops quickly, and their reinforcing properties make them a bad long-term 
treatment option. Benzodiazepines act at the --+ N-terminal domain interface of the GABAA 
receptor. Due to this site of action, benzodiazepines have effects only on GABAA receptors 
containing both an  and a  subunit. Benzodiazepines act as positive modulators of the GABAA 
receptors, meaning that, when applied alone, they exert no effect. Once GABA is bound, they can 
potentiate the GABAA receptor. Several mechanisms as to how this enhancement is produced have 
been described, including benzodiazepines decreasing the rates of GABA unbinding, increasing 
GABA binding rates, increasing single channel conductance and enhancing an intermediate pre-
activation step that occurs after GABA binding, but before channel opening (Twyman et al., 1989; 
Rogers et al., 1994; Eghbali et al., 1997; Campo-Soria et al., 2006; Bianchi et al., 2009; Gielen et 
al., 2012). Despite many hypotheses, there is still much unknown about how benzodiazepine 
binding is coupled to enhancement of receptor function.  
 
Receptors that consist of 1-3,5 in combination with 1-3 are sensitive to modulation by 
benzodiazepines, with 1 and 3 having reduced sensitivity to benzodiazepines compared to 2 
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subunit-containing receptors (Ymer et al., 1990; Herb et al., 1992). The histidine 101 residue in 
the 1 subunit plays an important role in benzodiazepine action and it is conserved in the 2,3,5 
subunits (Wieland et al.,1992; Benson et al., 1998). Receptors that contain the 4 or 6 subunit are 
insensitive to benzodiazepines as they have an arginine residue in place of the conserved histidine 
residue. Mutations of α subunits at the conserved histidine residue renders those receptors 
insensitive to benzodiazepine modulation. Knock-in mice expressing these benzodiazepine-
insensitive mutations in different subunits have demonstrated that specific GABAA receptor 
subunits mediate specific behavioral effects of benzodiazepines. The α1(H101R) mutant mouse, 
in which amino acid residue 101 has been mutated from histidine to arginine, is resistant to the 
sedating effects of benzodiazepines (Rudolph et al., 1999; McKernan et al., 2000). In contrast, the 
α2 (H101R) mutant mouse is resistant to the anxiolytic effects of benzodiazepines (Löw et al., 
2000; Morris et al., 2006). Additionally, mice that lack the α2-containing GABAA receptor, or have 
mutations that render their α2β3γ2 GABAA receptor benzodiazepine-insensitive, show diminished 
anti-hyperalgesic effects in response to benzodiazepines, indicating a possible therapeutic role of 
benzodiazepines for hyperalgesia (Paul et al., 2014).  
 
The literature is conflicted over which α subtype mediates the ‘addictive’ properties of 
benzodiazepines. 1,2,3 and 5 containing GABAA receptors have all been implicated. Drug 
addiction involves complex changes in brain circuitry, gene expression and receptor function, and 
an important aspect believed to be involved in this process is the increase in dopamine signaling 
from the ventral tegmental area to the nucleus accumbens (Gonzales et al., 2004). GABAergic 
neurons that project from the nucleus accumbens to the ventral tegmental area normally inhibit 
these dopaminergic neurons from firing. Drugs of abuse that act on the GABAA receptor (in 
addition to opioids and cannibinoids) are thought to produce a disinhibition of dopamine neurons 
in the ventral tegmental area, thereby increasing the release of dopamine into the nucleus 
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accumbens (Kalivas et al., 1990; Johnson and North, 1992; Szabo et al., 2002; Tan et al., 2010). 
α1(H101R) knock-in mice do not develop preference for benzodiazepines, and ventral tegmental 
area brain slice recordings show that this mutation in the α1 subunit prevents benzodiazepines from 
disinhibiting dopamine firing (Tan et al., 2010). However, a more recent study found that 
stimulation of both 1- and 2- containing GABAA receptors in the nucleus accumbens may 
contribute to the reinforcing properties of benzodiazepines (Engin et al., 2014; Ralvenius et al., 
2015). Another study found that 2 and 3, but not 1, subunits are responsible for the rewarding 
effects of benzodiazepines (Reynolds et al., 2012). Yet other studies have suggested that the 3-
containing GABAA receptors are primarily responsible for the rewarding effects of BZDs (Shinday 
et al., 2013). Tolerance to the sedative effects of diazepam has been linked to benzodiazepine 
activity at both α1 and α5- containing GABAA receptors (van Rijnsoever et al., 2004). Perhaps these 
conflicting results suggest that the reinforcing effects of BZDs may require simultaneous 
stimulation of multiple subtype compositions of the GABAA receptors, and so selectively 
activating only one subtype of GABAA receptor may bypass the rewarding properties of 
benzodiazepines.  
 
Benzodiazepine-site acting drugs that do not produce pronounced potentiation of the 
GABAA receptor have also been identified. Ro 15-4513 produces a weak inhibitory effect at the 
GABAA receptor when added in combination with GABA, while flumazenil is termed a 
benzodiazepine-site antagonist. Since it is an anxiogenic compound, Ro 15-4513 is used for 
experimental purposes only, but flumazenil is used clinically to treat benzodiazepine overdose 
(Sivilotti, 2016). Flumazenil produces a very weak enhancement at the receptor when combined 
with GABA, but application of this compound will compete with a potentiating benzodiazepine, 
resulting in a decrease in the net amount of potentiation of GABAA receptor function (Mihic et al., 
1994).  
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1.4.1.2 Zinc Modulation of the GABAA receptor 
Zinc is a negative modulator of the GABAA receptor. Its degree of inhibition is subtype 
specific, with  receptors exhibiting greater sensitivity to zinc (low nanomolar) than  
receptors (high micromolar) (Draguhn et al., 1990; Smart et al., 1991). There are thought to be 
three distinct sites at the  GABAA receptor to which Zn2+ can bind, two at the extracellular  
interface, and one within the channel pore of the  subunit. 1 subunit residues glutamic acid 137 
and histidine 141 coordinate with  subunit glutamic acid 182 to form two identical sites at two 
separate  interfaces.  subunit residues histidine 267 and glutamic acid 270 contribute to the 
third binding site within the pore. Mutation of all these residues (at once) to alanine results in a 
receptor that is insensitive to the inhibitory effects of zinc even at a concentration of 10mM Zn2+ 
(Horenstein and Akabas, 1998; Hosie et al., 2003).  
 
Receptors that incorporate the 2 subunit are less sensitive to Zn2+, but mutating  subunit 
residues (arginine 197, isoleucine 282 and lysine 285) to mimic the histidine and glutamic acid 
residues in the  subunit thought to contribute to zinc binding (glutamic acid 182, histidine 267, 
glutamic acid 270) partially restores sensitivity to low zinc concentrations (Hosie et al., 2003). The 
2 subunit-containing GABAA receptors are thought to contain two separate Zn2+ binding domains 
within the 2 subunit - one in the extracellular N-terminal domain and one near the channel pore 
(Nagaya and Macdonald, 2001). Delta- or epsilon-containing GABA receptors appear to be less 
sensitive to Zn2+ than  receptors, but more sensitive than  receptors (Whiting et al., 1997; 
Kaur et al., 2009).  
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1.4.1.3 Neurosteroid Modulation of the GABAA receptors 
Several progesterone and deoxycorticosterone metabolites, known as neurosteroids, are 
capable of positively or negatively modifying the GABAA receptor.  Neurosteroids that increase 
GABAA receptor function can act as anaesthetics and have therapeutic potential for the treatment 
of insomnia, epilepsy and anxiety (Zorumski et al., 2000). The neurosteroids 5a-pregnan-3a-ol-
20-one (allopregnanolone) and 3α,21-dihydroxy-5α-pregnan-20-one (THDOC) are endogenous 
positive modulators of GABAA receptors (Wang, 2011). Low concentrations of neurosteroids are 
capable of allosteric modulation of the receptor, while high concentrations directly activate the 
receptor through a separate binding site. Modulation of the receptor by neurosteroids seems to be 
dependent on several residues located in TMD1 and TMD4 within the same  subunit, while direct 
activation of the GABAA receptor by neurosteroids is thought to occur after neurosteroid binding 
to a site formed by TMD2 of the  subunit and TMD2 of the  subunit (Hosie et al., 2006; Akk et 
al., 2008; Hosie et al.,2008; Bracamontes et al., 2012). However, more recent crystal structures of 
chimeric receptors with bound THDOC have suggested that the modulatory site of neurosteroids 
is also formed by an intra-subunit pocket, with TMD1 from one subunit coordinating with TMD2 
of the adjacent subunit (Laverty et al., 2017; Miller et al., 2017). The presence of the  subunit 
versus the  does not change receptor potentiation by neurosteroids, further suggesting that 
neurosteroid modulation and activation only requires the  and  subunits (Hosie et al., 2008). 
 
Neurosteroids, such as pregnanolone sulfate, that induce an inhibitory allosteric response 
in the GABAA receptor, are thought to bind to a separate site from the positive allosteric 
neurosteroid site (Akk et al., 2001). Crystal structures of GABAA receptor chimeras suggests that 
pregnanolone sulfate binds perpendicularly to the membrane in a pocket formed by TMD3 and 
TMD4 within the same  subunit (Laverty et al., 2017). While studies have proposed that 
inhibitory neurosteroids may act to increase receptor desensitization, the mechanism of how 
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inhibitory neurosteroid binding affects channel function is still unclear (Shen et al., 2000; Akk et 
al., 2001).  
  
1.4.1.4 Ethanol Modulation of the GABAA Receptor 
While ethanol acts as a negative allosteric modulator of excitatory NMDA receptor 
function, it acts as a positive allosteric modulator of the  and  GABAA receptor (Nakahiro 
et al., 1991; Reynolds et al., 1992; Tatebayashi et al., 1998). Two amino acids in the 1 subunit 
TMD2 (serine 270) and TMD3 (alanine 291), and one in the 1 subunit TMD2 (serine 265) 
influence ethanol modulation of the GABAA receptor. 1 residue serine 267 plays the most direct 
role in alcohol binding and determines how large of an alcohol molecule can bind (Mihic et al., 
1997; Ueno et al., 1999; Mascia et al., 2000; Jung and Harris, 2006). Apart from the potentiating 
site, short-chain alcohols can also bind to an inhibitory site of the GABAA receptor, with the net 
effect of these short chain alcohols determined by their actions at both sites. Threonine 261 in the 
2 subunit TMD2 may mediate the inhibitory action of alcohols, with mutation of this site to 
tryptophan resulting in greater enhancement of receptor function by small-chain alcohols (Ueno et 
al, 2000; Johnson et al., 2012). On the single channel level, the addition of alcohol results in an 
increase in frequency of channel opening, the mean open time, burst frequency and burst duration, 
while decreasing the amount of time the receptor spends in the closed state (Tatebayashi et al., 
1998). 
 
Different receptor subtypes vary in their responses to ethanol, with the most prevalent 
GABAA receptor,  receptors, exhibiting low sensitivity to ethanol.  receptors have been 
proposed as the “one drink target” for low concentrations of ethanol, but the alcohol sensitivity of 
these receptors is debated. While some studies suggest  receptors are enhanced by low 
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concentrations (1-30mM) of ethanol, others have failed to see this effect (Sundstrom-Poromaa et 
al., 2002; Wallner et al., 2003; Borghese et al., 2006; Yamashita et al., 2006; Baur et al., 2009). 
Mutagenesis studies have pointed at the alcohol binding site in  receptors to be at the N-
terminal +/- interface-the interface that does not bind GABA (Wallner et al., 2014). Further, 
these low ethanol effects on  receptors may be antagonized by Ro 15-4513, the 
benzodiazepine-site inverse agonist, which is also hypothesized to have a site of action on 
benzodiazepine-insensitive receptors (Hanchar 2006; Wallner et al., 2006; Wallner et al., 2014).   
 
The GABA rho receptor lacks the potentiating alcohol-binding site (it has an isoleucine 
residue in place of serine 270) present in  and  receptors and thus alcohols inhibit rho 
receptor function.  A threonine residue (T298) in TMD2 of the rho subunit is thought to be key in 
producing this inhibitory response.  (Wick et al., 1998; Borghese et al., 2015).  
 
1.4.2 GLYCINE RECEPTORS 
Glycine, while acting as a co-agonist for excitatory NMDA receptors, can also act as an 
agonist at inhibitory glycine receptors. These receptors belong to the cys-loop family of receptors, 
are anion conducting, and mediate inhibitory synaptic transmission. These receptors are composed 
of  subunits, and are sometimes expressed with a  subunit. To date, four different  subunits 
one  subunit have been identified. While each  subunit arises from a separate gene product, the 
 subunits share over 90% sequence identity. Glycine receptors, while originally thought to be 
localized to the spinal cord, are expressed throughout the central nervous system, including in the 
nucleus accumbens, hippocampus, and in thalamic and brainstem nuclei (Zarbin et al., 1981; Colin 
et al., 1998; Ghavanini et al., 2005; Molander and Soderpalm, 2005). 
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Glycine receptors can exist as homomers, with five identical copies of the same  subunit, 
as  subunit heteromers, or as  heteromers.  homomers are not believed to form functional 
receptors (Bormann et al., 1993). The glycine receptor agonist site is at the interface of two 
adjacent subunits, resulting in a glycine receptor having five possible binding sites for glycine. 
The receptor, as with all cys-loop receptors, is thought to follow a concerted model of opening, 
where a single molecule binding to an agonist site results in all subunits undergoing simultaneous 
conformational changes, resulting in channel opening (Corringer et al., 2000). Gating efficacy 
increases as more glycine agonists bind to the remaining four sites, with maximal efficacy achieved 
when only three of the five sites are occupied (Beato et al., 2004). There is little difference in 
glycine sensitivity between subunits (Lynch, 2004).  
 
1.4.2.1 Zinc Modulation of the Glycine Receptor 
Zinc acts as a biphasic modulator of the glycine receptor. At low (nanomolar) 
concentrations, zinc potentiates glycine receptor responses, while high concentrations (>10M) 
inhibit the receptor. This is thought to be due to the presence of two distinct zinc binding sites on 
the glycine receptor. Several residues have been implicated in the potentiating effects of zinc. 
Mutagenesis of aspartic acid 80 of the 1 subunit disrupts zinc enhancement of glycine-activated 
currents, but not taurine-activated currents, complicating this residue's involvement in zinc binding 
to its high affinity potentiating site (Laube et al., 2000). Further mutagenic studies have found that 
alanine substitution of histidine 215 significantly reduces zinc potentiation of receptor function, 
while alanine substitution of glutamic acid 192 and aspartic acid 194 eliminates the enhancing 
action by zinc (Miller et al., 2005). Interestingly, serine substitution of tryptophan 170 also 
eliminates zinc potentiation, and this is thought to be due to disruption of the zinc binding site 
formed by the previously mentioned residues (Zhou et al., 2013; Cornelison et al., 2017). The low 
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affinity zinc inhibition site is thought to bind zinc via the coordination of two histidine residues 
(H107, H109) at the N-terminal interface of two adjacent subunits. Mutation of these histidine 
residues eliminates the inhibitory effects seen at high zinc concentrations (Harvey et al., 1999; 
Nevin et al., 2003).  
 
1.4.2.2 Ethanol Modulation of the Glycine Receptor 
Ethanol potentiates glycine receptor function, and the receptor is more sensitive to lower 
concentrations of ethanol than the  GABAA receptor. On the single channel level, ethanol acts 
by increasing channel burst duration by reducing the rate of glycine unbinding from the receptor 
(Welsh et al., 2009). Through chimeric constructs and mutagenesis, amino acids in the 1 subunit 
TMD2 (serine 267) and TMD3 (alanine 288) were found to play an important role in ethanol 
modulation of the receptor (Mihic et al., 1997). The residue present at position 267 in the 1 
subunit can determine the extent of potentiation produced in the receptor by ethanol. A large 
residue in position 267 results in ethanol allosterically inhibiting the receptor, while small residues 
(like the serine present in wildtype receptors) allow ethanol to potentiate the receptor (Ye et al., 
1998).  
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1.5 Targeting GABAA, Glycine and NMDA Receptors for the Treatment of 
Disease 
NMDA, GABAA and glycine receptors play a major role in the excitatory and inhibitory 
transmission in the brain, thus it is not surprising that they have therapeutic potential for a large 
range of indications. These indications include, but are not limited to, anxiety, depression, drug 
abuse, epilepsy, pain, Alzheimer’s disease, Parkinson’s disease, schizophrenia and stroke. 
 
1.5.1 ANXIETY AND DEPRESSION 
Ketamine, which acts as an open channel blocker of the NMDA receptor, has recently 
shown promise as a fast-acting antidepressant (Berman et al., 2000; DiazGranados et al., 2010). 
While it is unclear how ketamine is producing its anti-depressant effects, it has brought attention 
to the NMDA receptor for its therapeutic potential in treating depression (Zanos and Gould, 2018). 
Antagonists at the glycine co-agonist site (e.g. AV-101) have also generated interest for their anti-
depressant effects (Przegalinski et al., 1997; Duman, 2018).  
 
Ligands selective for 1- containing GABAA receptors (e.g.zolpidem) are used clinically 
to treat insomnia, while the 2 containing GABAA receptor is a target for non-sedating anxiolytics 
(Löw et al., 2000; McKernan et al., 2000; Morris et al., 2006). However, drugs (eg. TPA-023, a 
partial agonist at 2/3 GABAA receptors) targeting the 2 subtype have failed to make it through 
the clinical trial process (Atack, 2008; Ator et al., 2010; Mohler, 2011). Activation of the glycine 
receptor with taurine produces an anxiolytic response, suggesting a possible role of glycine 
receptors in mediating anxiety responses (Zhang and Kim, 2007).  
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1.5.2 DRUG ABUSE 
NMDA receptor modulators have been implicated in the treatment of drug addiction and 
alcoholism (Tomek et al., 2013). Excitatory synapses on ventral tegmental dopaminergic neurons 
are strengthened by drugs of abuse, through the cell membrane insertion of GluR2-lacking (Ca2+ 
permeable) AMPA receptors. NMDA receptor antagonists can block this strengthening from 
occurring (Ungless et al., 2001; Saal et al., 2003). Additionally, the NMDA receptor negative 
modulator (uncompetitive antagonist) memantine has shown clinical promise in reducing cue-
induced craving in alcoholics (Krupitsky et al., 2007).  
 
Potentiators and inhibitors of GABAA receptor function also show clinical promise for 
aspects of drug use and dependence. While benzodiazepines are often clinically used to ease 
patients out of alcohol withdrawal, the abuse liability associated with benzodiazepines themselves 
leaves a lot to be desired as a drug withdrawal antidote (Liang and Olsen, 2014). However, the 
effect of GABAA receptor potentiation on alcohol withdrawal validates the receptor as a target for 
treatment of drug abuse. This is supported by the actions of flumazenil, which is used to counteract 
benzodiazepine overdose, and the inverse benzodiazepine-site agonist Ro 15-4513, which 
antagonizes the behavioral effects of alcohol, and reduces alcohol consumption in rodents (Suzdak 
et al., 1988; June et al., 1991).  
 
Glycine receptor acting drugs may also have therapeutic potential for drug abuse. The 
increase in dopamine transmission into the nucleus accumbens after alcohol consumption in 
rodents is dependent on glycine receptor activation, with a glycine receptor antagonist preventing 
this increase (Molader and Soderpalm, 2005; Jonsson et al., 2014). Additionally, there is evidence 
that pharmacological activation of glycine receptors (essentially mimicking alcohol potentiation 
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of glycine receptors) in the ventral tegmental area or nucleus accumbens decreases alcohol 
consumption (Molander et al., 2005; Li et al, 2012).  
 
1.5.3 PAIN 
NMDA, GABAA and glycine receptors are all implicated in pain pathways. The 3 glycine 
receptor is highly expressed in the spinal cord dorsal horn and is inhibited by prostaglandin E2’s 
activation of protein kinase A. Protein kinase A activation leads to internalization of the 3 receptor 
and decreases receptor function (Ahmadi et al., 2002; Harvey et al., 2004). Decreased 3 receptor 
number and function results in an increase in nociceptive pain signaling to the brain; therefore, 
increasing glycine receptor function may be of therapeutic interest for the treatment of pain.  
 
Additionally, glutamate-induced neurodegeneration of GABAergic neurons in the dorsal 
horn may play a role neuropathic pain, with selective deletion of NMDA receptors in the dorsal 
horn decreasing the amount of neurodegeneration and pain observed in rodents (Inquimbert et al., 
2018). Additionally, numerous other studies have shown that blocking NMDA receptors can 
relieve pain in rodent models (Davar et al., 1991; Ren et al., 1992; Mao et al., 1993). Enhancing 
the lost GABAergic transmission in the dorsal horn may also relieve pain by re-establishing the 
fine balance between excitation and inhibition (Koga et al., 2017).  
 
1.5.2 OTHER DISORDERS 
Epilepsy can result from the imbalance between excitation and inhibition in the brain (i.e. 
too much excitation and/or too little inhibition). Thus it is unsurprising, given the NMDA 
receptor’s role in excitatory transmission, that a reduction in NMDA transmission may be 
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beneficial in the treatment of epilepsy (Urbanska et al., 1998). Felbamate, which may in part exert 
its actions via NMDA receptor blockade, has anti-convulsant effects (Subramaniam et al., 1995). 
Despite multiple animal studies promising anti-convulsant effects from other inhibitors of NMDA 
receptor function (e.g. dizocilpine, a non-competitive NMDA receptor antagonist), contradictory 
results and undesirable side effects in animal studies have thus far hindered their progress to the 
clinic (Wong et al., 1986; Sato et al., 1988; Ormandy et al., 1989; Wozniak et al., 1996; Ghasemi 
and Schachter, 2011).  
 
The role of GABAA receptors in epilepsy is evidenced by mutant receptors (such as the 
K289M mutation in the 2 subunit), where abnormal GABA pharmacology is associated with 
epileptic seizures (Baulac et al., 2001; Audenaert et al., 2006). Barbiturates, positive allosteric 
modulators of the GABAA receptor, were the first drugs to be used in the treatment of epilepsy. 
Benzodiazepines remain first in line for status epilepticus and are sometimes prescribed for 
prophylactic purposes, but their abuse potential and sedative effects calls for the use of other agents 
and the development of GABAA receptor subunit selective anti-epileptic drugs (Ochoa et al., 
2016). Similarly, RNA editing of 2 and 3 glycine receptors results in receptors with enhanced 
receptor function, and is associated with temporal lobe epilepsy (Meier et al., 2005; Eichler et al., 
2008; Eichler et al., 2009). Selectively blocking these receptors would be therapeutically 
beneficial. 
 
An over-activation of NMDA receptors, leading to an excess of Ca2+ influx and 
excitotoxicity-mediated cell death, is believed to contribute to other neurological disorders besides 
epilepsy, such as Alzheimer’s disease, Parkinson’s disease and stroke (Mody and Macdonald, 
1995; Bleich et al., 2003). While NMDA receptor modulators have shown therapeutic potential 
for these indications in animal models, only memantine (a negative NMDA receptor modulator 
 30 
used to treat Alzheimer’s) has made it to the clinic (Hallett and Standaert, 2004; Hoyte et al., 2004; 
Olivares et al., 2012). This setback may be due to a lack of specificity of antagonists studied, 
resulting in unwanted side effects, and has resulted in a shift for pharmaceutical companies to look 
towards more specific NMDA receptor modulators, or to instead target pathways downstream from 
NMDA receptors (Olney et al., 1989; Vandame et al., 2013; Wu et al., 2018). 
 
In this dissertation, I investigated several components of allosteric modulation. First, I 
identified the endogenous ketone bodies acetone and -hydroxybutyric acid as allosteric 
modulators of the NMDA, GABAA and glycine receptor. This allosteric modulation may have 
therapeutic benefit for the various indications mentioned above. Second, I investigated the 
molecular mechanism of benzodiazepine action with the goal of gaining insight towards how to 
achieve drug selectivity. Lastly, I utilized phage display technology to identify peptides capable 
of modulating the 2 GABAA receptor, in hopes of finding a non-sedative anxiolytic that may also 
have other therapeutic indications. 
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CHAPTER 2: KETONE BODY MODULATION OF LIGAND-GATED ION 
CHANNELS1 
 
2.1 Introduction 
Ketogenesis, the production of ketone bodies from fatty acids, occurs constantly at low 
rates in the human body.  Under certain conditions, however, such as in situations of low blood 
glucose, ketogenesis becomes the body's main energy resource.  Fatty acids are broken down in 
liver mitochondria into acetyl-CoA molecules, which at high levels can overwhelm the citric acid 
cycle.  Acetyl-CoA is then instead further metabolized in a series of steps into the ketone body 
acetoacetate, which itself breaks down into the ketone bodies acetone and -hydroxybutyrate.  
While -hydroxybutyrate is not technically a ketone, as its carbonyl side group is only attached to 
one carbon not two, it is frequently referred to as a ketone body.  Acetone is a small polar molecule 
that readily diffuses away from the liver to be metabolized further into D-lactate, pyruvate and 
glucose (Glew, 2010).  The liver is unable to use acetoacetate and -hydroxybutyrate as metabolic 
fuel due to a lack of succinyl CoA transferase (Williamson et al., 1971; Orii et al., 2008), an 
enzyme necessary for the re-conversion of acetoacetate and -hydroxybutyrate back to acetyl-
CoA.  Instead, acetoacetate and -hydroxybutyrate diffuse away from the liver to other regions, 
and can even pass into the brain via monocarboxylate transporters (Leino et al., 2001; Kim & Rho, 
2008).  
Excessive production of ketone bodies can result in ketoacidosis, in which the blood pH 
dips to dangerously low levels.  Risk factors for ketoacidosis include type I diabetes and heavy 
alcohol consumption, although it is not clear if acidosis is produced by alcohol consumption 
                                                 
1 This chapter details work that has been accepted for publication. Pflanz N.C. was responsible for the design, 
conduction and analysis of these experiments and for writing the manuscript. 
Pflanz N.C., Daskowzski A.W., James, K.A., Mihic S.J. Ketone Body Modulation of Ligand-Gated Ion Channels (2018) Neuropharmacology. 
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directly, or perhaps indirectly by other factors such as poor nutrition seen in individuals who 
consume high quantities of alcohol (Lefevre et al., 1970; Cooperman et al., 1974; Fulop & 
Hoberman, 1979; Derr et al., 1983; Wrenn et al., 1991; Sarkola et al., 2002; Misra & Oliver, 2015;).  
Despite negative consequences arising from high levels of ketone bodies, the ketogenic diet, 
involving low carbohydrate and high fat intake, has been used to effectively control epileptic 
seizures since the 1920s (Wilder, 1921).  Development of anti-seizure compounds decreased the 
use of the ketogenic diet as a therapeutic tool but its use resurfaced in the 1990s after multiple 
studies demonstrated its efficacy (Freeman et al., 1998; Vining et al., 1998).  Since then the 
ketogenic diet has been therapeutically linked to the amelioration of other disease states, including 
alcohol withdrawal syndrome, Parkinson’s disease, amyotrophic lateral sclerosis, schizophrenia 
and Alzheimer’s disease (Reger et al., 2004; Vanitallie et al., 2005; Siva, 2006; Kraft & Westman, 
2009; Yang & Cheng, 2010; Shaafi et al., 2016; Dencker et al., 2018; Taylor et al., 2018). 
 Despite the various clinical indications for which a ketogenic diet may be used, its 
mechanisms of action remain to be elucidated.  Multiple hypotheses have been suggested, 
including enhancement of GABAergic transmission, antagonism of glutamatergic transmission, 
increases in potassium channel activity, purinergic transmission or BDNF expression, changes in 
metabolic factors, increased antioxidant effects or an increase in, and subsequent actions of, 
polysaturated fatty acids (De Vivo et al., 1978; Erecińska et al., 1996; Yudkoff et al.,1997; Yudkoff 
et al., 2001; Deransart et al., 2003; Fraser et al., 2003; Wang et al., 2003; Dahlin et al., 2005; 
Bough et al., 2006; Ma et al., 2007; Maalouf et al., 2007; Yang et al., 2007; Juge et al., 2010; 
Masino et al., 2011; Tanner et al., 2011; Sleiman et al., 2016).  
 The beneficial effects of a ketogenic diet to treat both epilepsy and alcohol 
withdrawal syndrome led us to hypothesize that ketone bodies would have direct effects on the 
receptors implicated in these disorders.  This chapter reports on the modulatory effects of -
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hydroxybutyrate and acetone on neurotransmitter-activated NMDA, GABAA and glycine 
receptors. 
 
2.2 Methods 
2.2.1 REAGENTS 
All reagents used in this study were purchased from Sigma-Aldrich (St. Louis, MO), unless 
otherwise stated. 
 
2.2.2 DNA PREPARATION & SITE-DIRECTED MUTAGENESIS 
Human cDNAs encoding the 1, 2 and 2 GABAAR subunits, the 1 glycine receptor 
subunit (subcloned into the pBK-CMV vector), and NR1, NR2A and NR2B NMDA receptor 
subunits (subcloned into the pCDNA1 vector) were used in this study.  The 1, 2 and 2 GABAAR 
subunit DNAs were injected into oocytes at a concentration of 1.5ng/30nl in a 1:1:10 ratio to ensure 
incorporation of the 2 subunit.  The 1 glycine receptor DNA was also injected at this 
concentration.  Point mutations were introduced into the 1 glycine and the NR1 NMDA receptor 
subunits using a QuikChange site-directed mutagenesis kit (Agilent Technologies, CA).  Double-
stranded DNA sequencing confirmed the introduction of these mutations.  
 
2.2.3 PREPARATION OF CRNA 
Human cDNAs encoding the NR1, NR1F639A, NR2A and NR2B genes were linearized with 
the restriction enzymes XbaI (NR1, NR1F639A) or XhoI (NR2A, NR2B) (New England Biolabs, 
MA) and transcribed into cRNA using the mMessage mMachineTM T7 transcription kit (Thermo 
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Fisher Scientific, MA).  NR1 was mixed with either NR2A or NR2B, and NR1F639A was mixed 
with NR2A, in a 1:1 ratio and 1.5ng/30nl of each cRNA mixture was injected into each oocyte. 
 
2.2.4 COLLECTION AND PREPARATION OF XENOPUS LAEVIS OOCYTES 
Xenopus laevis (Nasco, WI) were housed in an Association for Assessment and 
Accreditation of Laboratory Animal Care International (AAALAC) accredited facility in a room 
kept at 17°C and a 12h light/dark cycle, in tanks monitored for water pH and conductivity.  Oocytes 
were surgically removed in accordance with the National Institute of Health guidelines under a 
protocol approved by the IACUC of the University of Texas at Austin, and placed in a hypertonic 
solution (108 mM NaCl, 1 mM EDTA, 2 mM KCl, and 10 mM HEPES).   The thecal and epithelial 
layers of Stage V and VI oocytes were manually removed using forceps.  Isolated oocytes were 
transferred to a solution (83 mM NaCl, 2 mM KCl, 1 mM MgCl2 and 5 mM HEPES) containing 
0.5 mg/mL collagenase from Clostridium histolyticum for 10 minutes in order to enzymatically 
remove the follicular layer of the oocytes.  The animal poles of oocytes were then injected using a 
Nanoject II (Drummond Scientific Co., PA) with 1.5 ng/ 30nL of human 1, 2 and 2 GABAA 
receptor subunit cDNAs in a 1:1:10 ratio.  cRNA was injected into the oocyte cytoplasm at the 
interface of the animal and vegetal poles. Oocytes were stored singly in 96-well plates containing 
incubation media (88 mM NaCl, 1 mM KCl, 2.4 mM NaHCO3, 10 mM HEPES, 0.82 mM 
MgSO4•7H2O, 0.33 mM Ca(NO3)2, 0.91 mM CaCl2, 2mM sodium pyruvate, 0.5 mM theophylline, 
10 U/L penicillin, 10 mg/L streptomycin).  The oocytes were kept at room temperature (20°C) and 
away from light. 
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2.2.5 TWO-ELECTRODE VOLTAGE CLAMP ELECTROPHYSIOLOGY 
Electrophysiological recordings were performed on oocytes 1-3 days post-injection. 
Individual oocytes were placed in a 100L bath and continuously perfused at a rate of 2ml/min 
with buffer, which differed depending on the receptor under study.  
Oocytes expressing GABAA receptors were perfused with ND-96 (96mM NaCl, 2mM 
KCl, 1.8mM CaCl2, 1mM MgCl2, 5mM HEPES, pH 7.4), while oocytes expressing glycine 
receptors were perfused with modified Barth's solution (88mM NaCl, 1mM KCl, 2.4mM NaHCO3, 
10mM HEPES, 0.82mM, MgSO4·7H2O, 0.33mM Ca(NO3)2, and 0.91mM CaCl2, pH 7.5).  
NMDA receptor-expressing oocytes were perfused with Ca2+ free frog Ringer’s solution (115mM 
NaCl, 2.5mM KCl, 10mM HEPES, 1.8mM BaCl2, pH 7.2). 
 
Animal poles of oocytes were impaled with two 3M KCl-filled borosilicate glass 
electrodes, each with a resistance between 0.5 and 10MΩ.  Oocytes were voltage clamped at -
70mV (GABAA receptor expressing oocytes were clamped at -80mV) using an OC-725 oocyte 
clamp (Warner Instruments, CT) and data was collected at a rate of 1 kHz using a digitizer 
(PowerLab ML866) and LabChart (v. 7.4.7) software (both from ADInstruments, Australia). 
 
2.2.6 TESTING RECEPTOR MODULATION BY ZINC, ETHANOL, ACETONE AND -
HYDROXYBUTYRIC ACID  
An oocyte was exposed to a maximally-effective concentration of agonist (GABA for 
GABAAR, glycine for glycine receptor, L-glutamic acid + 10M glycine for NMDAR) applied for 
30 seconds. After this, a concentration which produced 5-10% of this maximal response (termed 
EC5-10) was determined.  This agonist EC5-10 was repeatedly applied at 4 minute intervals until 
responses were stable.  Once stable, increasing concentrations of modulator [zinc (30nM-100M), 
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ethanol (10-300mM), acetone (10-1000mM) or -hydroxybutyric acid (100uM-6mM)] were 
applied to the receptor in combination with the EC5-10 agonist, preceded by a 10 second pre-
application of modulator alone.  While the maximal blood alcohol limits for legally operating 
vehicles in many countries is 0.08% (~22mM), blood ethanol concentrations above 300 mM, while 
rare, have been attained and survived (O'Neill et al., 1984).  Receptor modulation was assessed as 
[(Iagonist + Modulator/Iagonist)-1] *100, where I is the current evoked.  This experiment was repeated with 
2.5mM of the zinc chelator tricine added to the bath buffer, and again at maximally effective 
agonist concentrations. 
 
2.2.7 TESTING THE EFFECTS OF ACETONE AND -HYDROXYBUTYRIC ACID IN COMBINATION 
WITH ETHANOL 
Oocytes expressing NMDA receptors were exposed to a concentration of l-glutamine plus 
10M glycine to elicit its maximal response.  The NMDAR EC5-10 was subsequently determined, 
and repeatedly applied at 4 minute intervals until stable responses were observed.  Increasing 
concentrations of ethanol (10mM-300mM) were applied in combination with the NMDAR EC5-
10, and receptor modulation was calculated as described above. This experiment was repeated in 
the presence of Ca2+ free frog Ringers solution that contained either 30mM acetone or 300M -
hydroxybutyric acid. 
 
2.2.8 DETERMINATION OF ZINC CONTAMINATION IN ACETONE AND -HYDROXYBUTYRIC ACID. 
10mM acetone and 1mM -hydroxybutyric acid were prepared in BDTM Falcon 
polypropylene tubes (Thermo Fisher Scientific, MA) containing 2% HNO3 in ultrapure H2O.  Zinc 
concentrations of these two tubes plus a control tube (containing only the 2% HNO3 in ultrapure 
H2O) were determined using a quadrupole-based Agilent inductively coupled plasma mass 
 37 
spectrometer (ICP-MS) at the Jackson School of Geosciences Isotope Geochemistry Facility at the 
University of Texas at Austin. 
2.3 Results 
2.3.1 THE KETONE BODIES ACETONE AND -HYDROXYBUTYRIC ACID DECREASE NMDA-R 
FUNCTION 
Acetone decreased NMDA receptor function in a concentration-dependent manner 
(Figures 4A, 5A and 5B) with threshold concentrations of approximately 10 - 30mM.  Two 
NMDA receptor subtypes (NR1 + NR2A and NR1 + NR2B) were characterized for their 
sensitivities to acetone when acetone was co-applied with either a glutamate concentration 
producing maximal receptor activation (EC100) or 5-10% maximal activation (EC5-10).  There was 
no significant difference between the two NMDA receptor subtypes (NR1 + 2A versus NR1 + 2B) 
in their sensitivities to acetone inhibition of glutamate EC5-10 [F(1,37)=0.51, p>0.48,  or EC100 
[F(1,26)=0.41, p>0.53].  The  magnitude of acetone modulation was independent of glutamate EC 
value (see Figure 5 legend for statistics).  -hydroxybutyric acid was also able to negatively 
modulate both NMDA receptor subtypes in a concentration-dependent manner (Figures. 4B, 5C, 
5D). No significant differences were found between NR1 + NR2A versus NR1 + NR2B receptor 
subtypes at glutamate EC100 [F(1,33)=.29, p>0.6].  However, a small difference was found between 
the two receptor subtypes using glutamate EC5-10 [F(1,29)=5.45, p<0.03].  Receptor modulation 
by -hydroxybutyric acid was dependent on glutamate concentration, with greater inhibition seen 
at higher glutamate concentrations (see Figure 5 legend for statistics). 
  
 38 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Sample tracings showing the effects of 100mM acetone and 100uM -
hydroxybutyric acid on NMDA NR1 + NR2A receptor function.  
A.  A maximally-effective concentration of 1mM glutamate (plus 10M glycine) was applied for 
30 seconds and the resulting current measured (left tracing).  Pre-incubation with 100mM acetone 
for 10 seconds and then co-application with glutamate plus glycine for 30 sec resulted in a 
decreased current (right tracing). B.  A maximally-effective concentration of 1mM glutamate with 
10M glycine was applied to the NMDA receptor without (left tracing) or with 100M -
hydroxybutyric acid (right tracing).  
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Figure 5. The ketone bodies acetone and -hydroxybutyric acid decrease NMDA receptor 
function.  
 Acetone and -hydroxybutyric acid effects were assayed at glutamate concentrations producing 
either maximal (EC100, hollow squares) or 5-10% of maximal (EC5-10, black circles) NMDA 
receptor responses.  Each symbol represents data from 3-6 oocytes obtained from at least two 
separate frogs, and error bars represent the mean ± standard error.  In some cases error bars fall 
within the symbols.  A. The NR1 + NR2A NMDA receptor exhibited a decreased response to 
glutamate when exposed to increasing concentrations of acetone [F(3, 29) = 137.9, p<0.0001].  
The degree of acetone inhibition was the same at EC5-10 and EC100 glutamate concentrations 
[F(1,29)=0.2, p>0.66].  B.  Increasing concentrations of acetone also decreased the responses of 
the NR1 + NR2B NMDA receptor [F(3,34) = 59.4, p<0.0001], with no effect of glutamate 
concentration [F(1,34)=0.46, p>0.5].  C.  NR1 + NR2A NMDA receptor function decreased in 
response to increasing concentrations of -hydroxybutyric acid [F(3,26)= 131.5, p<0.0001].  There 
was a significant effect of glutamate concentration, with greater -hydroxybutyric acid effects 
observed when the higher glutamate concentration was used [F(1,26) = 18.93, p<0.001].  D.  -
hydroxybutyric acid antagonized NR1 + NR2B receptor function in a concentration-dependent 
manner [F(3,36)=165.7, p<0.0001], and again greater inhibition was seen at higher glutamate 
concentrations [F(1,36)=10.61, p<0.01]. 
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2.3.2 THE NR1 F639A MUTATION RENDERS THE NMDA RECEPTOR LESS SENSITIVE TO 
MODULATION BY ETHANOL, ACETONE AND -HYDROXYBUTYRIC ACID 
To confirm if the F639A amino acid substitution renders NMDA receptors less sensitive 
to ethanol modulation, as described in Ronald et al. (2001), ethanol (10-300mM) was applied to 
the NR1 + NR2A or NR1 F639A + NR2A mutant receptors in combination with a saturating 
glutamate concentration (Figure 6A).  We confirmed that the F639A NR1 mutation produced a 
significantly reduced receptor sensitivity to ethanol (see Figure 6 legend for statistics).  To probe 
if acetone would also produce a weaker effect on this mutant, acetone (10 - 300mM) was applied 
in combination with a saturating glutamate concentration (Figure 6B).  The F639A mutation 
resulted in significantly decreased receptor modulation by acetone (Figure 6B, hollow triangles) 
compared to wildtype NMDA receptors (Figure 6B solid circles).  -hydroxybutyric acid 
sensitivity was also decreased in the F639A receptors compared to wildtype receptors (Figure 6C 
hollow triangles compared to filled circles) when increasing concentrations of -hydroxybutyric 
acid were applied in combination with a saturating glutamate concentration.  
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Figure 6. Effects of the NR1 F639A mutation on NMDA receptor modulation by ethanol, 
acetone and -hydroxybutyric acid.   
A.  NR1 + NR2A NMDA receptor (black circles) function decreases when ethanol is applied in 
combination with a maximally-effective concentration of glutamate and glycine; in comparison 
the NR1 F639A + NR2A receptor mutant (hollow triangles) shows a decreased response to ethanol 
[F(1,23)= 68, p<0.0001]  B.  The NR1 F639A + NR2A mutant receptor (hollow triangles) also 
exhibits a decreased modulatory response to acetone compared to wildtype NR1 + NR2A receptors 
(filled circles) [F(1,30)=32, p<0.0001]  C.  The NR1 F639A + NR2A receptor (hollow triangles) 
also exhibits less inhibition in response to -hydroxybutyric acid than the wildtype receptor (filled 
circles) [F(1,33)=42.7, p<0.0001].  Each symbol represents data from 3-6 oocytes, from at least 
two separate frogs, and error bars represent the mean ± standard error.  In some cases error bars 
fall within the symbols.  
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2.3.3 ALCOHOL ACTS ADDITIVELY WITH KETONE BODIES AT THE NMDA RECEPTOR 
Since the F639A substitution altered ethanol, acetone and -hydroxybutyric acid 
sensitivities (Figure 6) we next tested if acetone and -hydroxybutyric acid would compete, act 
additively, or act synergistically with one another.  EC5-10 glutamate concentrations were applied 
to the NR1 + NR2A receptor in combination with increasing ethanol concentrations in the absence 
and presence of 30mM acetone (Figure 7A) or 300M -hydroxybutyric acid (Figure 7B).  No 
significant differences were found in the ethanol concentration-response curves in the absence or 
presence of acetone or -hydroxybutyric acid (see Figure 7 legend for statistics).  Similar results 
were obtained when this experiment was repeated using NR1 + NR2B receptors (data not shown).  
The lack of an increase or decrease in receptor modulation by ethanol in the presence of either 
acetone or -hydroxybutyric acid suggests an additive role of the two compounds with ethanol. 
We also probed for an additive role between -hydroxybutyric acid and acetone by applying 
increasing concentrations of -hydroxybutyric acid, in combination with a saturating glutamate 
concentration, in the absence and presence of 30mM acetone (Figure 7C). The addition of acetone 
produced no change in the -hydroxybutyric acid concentration-response curve, suggesting that 
-hydroxybutyric acid and acetone also act additively with one another. 
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Figure 7. Effects of combining NR1 + NR2A NMDA receptor modulators with each other.  
Increasing concentrations of ethanol decreased the NR1 + NR2A NMDA receptor response (filled 
circles) when applied to the receptor with a 5-10% maximal concentration of glutamate (EC5-10) 
and 10M glycine.  This effect was unaltered when (A) 30mM acetone (hollow diamonds) 
[F(3,6)=1.283, p>0.3] or (B) 0.3mM -hydroxybutyric acid (crosses) [F(3,6)=0.078, p>0.9] was 
present.   In these experiments, ethanol was pre-applied with or without acetone or -
hydroxybutyric acid for 30 sec before also being co-applied with glutamate and glycine for a 
further 40 sec.  Increasing concentrations of -hydroxybutyric acid were pre-applied in 
combination with a maximal concentration of glutamate (EC100) and 10M glycine (C, filled 
triangles). This effect was unaltered in the presence of 30mM acetone (C, hollow squares) 
[F(3,6)=0.591, p>0.6]. Each symbol represents mean data from three oocytes obtained from two 
frogs ± the standard error.  In some cases the error bars fall within the symbols. 
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2.3.4 ACETONE AND -HYDROXYBUTYRIC ACID HAVE OPPOSING MODULATORY EFFECTS ON 
THE  GABAA RECEPTOR 
Concentrations of acetone greater than 100mM positively modified the effects of EC5-10 
GABA (Figure 8A and 8B, left tracings), but not saturating concentrations of GABA (Figure 8B, 
right tracings).  -hydroxybutyric acid, in contrast, acted as a negative modulator at low GABA 
concentrations (Figure 8C), with concentrations as low as 100M producing inhibition at the 
receptor.  This negative modulation was also dependent on the GABA concentration, as this 
phenomenon was not seen at saturating concentrations of GABA (Figure 8D). 
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Figure 8.  GABAA receptor modulation by acetone and -hydroxybutyric acid.  
 A.  The GABAA receptor is positively modified by acetone in a concentration-dependent manner 
when acetone is co-applied with a GABA concentration eliciting 5% of the maximal GABA 
receptor response (GABA EC5).  B.  Acetone modulation of GABAA responses is only seen when 
low concentrations of GABA are used (two leftmost tracings), with no effects of acetone when it 
is co-applied with a maximally-effective concentration of GABA  (two rightmost tracings).  C.  -
hydroxybutyric acid acts as a negative modulator of the GABAA receptor, but is only able to exert 
its actions when applied in combination with low concentrations of GABA (D, two leftmost 
tracings) and not when applied in combination with a saturating concentration of GABA (D, two 
rightmost tracings).  Each symbol represents data collected from 4-8 oocytes, with error bars 
representing the mean ± standard error.  The error bars fall within some symbols. 
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2.3.5 ACETONE IS A WEAK POSITIVE ALLOSTERIC MODULATOR AT THE 1 GLYCINE RECEPTOR, 
AND THIS MODULATION IS DEPENDENT ON THE SIZE OF THE AMINO ACID RESIDUE OCCUPYING 
POSITION 267  
Acetone affected the wildtype glycine receptor only at high concentrations (>300mM) 
(Figure 9A).  The magnitude of this modulation was unchanged in the presence of the zinc chelator 
tricine (see Figure 9 legend for statistics), indicating that glycine receptor modulation by acetone 
is not zinc dependent, unlike other modulators of the glycine receptor such as ethanol.  To confirm 
that acetone modulation of the receptor is not zinc dependent, acetone was applied in combination 
with glycine to the W170S 1 receptor (Figure 9A).  No significant difference was found in 
W170S receptor versus wildtype receptor modulation by 1M acetone (see Figure 9 legend for 
statistics).  To test if mutating residue S267 of the glycine receptor would similarly affect ethanol 
and acetone potentiation, 200mM ethanol or 1M acetone was added in combination with glycine 
EC5-10 to wildtype 1 or S267A, S267I or S267Y 1 glycine receptors.  Increasing the size of the 
residue occupying position S267 decreased the magnitude of receptor potentiation by ethanol, and 
also decreased receptor potentiation by 1M acetone (Figure 9B).  In the S267Y 1 glycine receptor 
both ethanol and acetone inhibited receptor function.  
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Figure 9. Acetone acts as a weak positive allosteric modulator at the 1 glycine receptor.  
A. 1M acetone enhanced 1 glycine receptor function when applied to the receptor in combination 
with a glycine concentration capable of 5-10% receptor activation (glycine EC5-10).  Acetone was 
pre-applied to the oocyte alone for 10 seconds before also being applied with glycine for 30 sec.  
The addition of the zinc chelator tricine to the buffer did not change glycine receptor modulation 
by glycine.  Application of acetone in combination with glycine to the W170S 1 glycine receptor 
mutant, a receptor which does not respond to the enhancing effects of zinc, also produced no 
change in receptor modulation by acetone.  A one-way ANOVA revealed no significant 
differences among the three conditions [F(2,15)=0.18, p>0.83].  Each bar represents data from 6 
oocytes from at least 2 frogs, with error bars representing the standard error of the mean.  B.  The 
amino acid size at position S267 of the glycine receptor affects ethanol potentiation, with 
increasing size resulting in decreased potentiation by ethanol. A one-way ANOVA revealed a 
significant effect of receptor mutation on ethanol modulation [F(3,13)=65.03, p<0.0001], and a 
Dunnett’s multiple comparisons test found that the S267I and S267Y receptor mutant responses 
were significantly different from those of wildtype glycine receptors.  Altering amino acid size at 
position 267 also significantly affected glycine receptor modulation by 1M acetone 
[F(3,30)=98.73, p<0.0001], with Dunnett’s multiple comparisons tests showing significant 
differences in acetone modulation by all S267 mutants compared to wildtype receptors.  Each bar 
represents data obtained from 3-8 oocytes from at least 2 frogs, ± the standard error of the mean. 
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2.3.6 -HYDROXYBUTYRIC ACID IS A NEGATIVE MODULATOR OF THE GLYCINE RECEPTOR 
-hydroxybutyric acid inhibited glycine receptor function, in a concentration-dependent 
fashion (Figure 10A) and slightly greater inhibition was seen in the presence of the zinc chelator 
tricine (Figure 10A, hollow circles).  Zinc acts as a biphasic modulator at glycine receptors, 
increasing glycine receptor function at nanomolar concentrations, and decreasing receptor function 
at higher, micromolar, concentrations (Figure 10B, filled circles).  The W170S glycine receptor 
is insensitive to the potentiating effects of zinc, but retains the negative modulation produced by 
higher concentrations of zinc (Figure 10B, filled triangles).  In contrast, the H109A glycine 
receptor is less sensitive than wildtype receptors to the inhibitory effects of zinc (Figure 10B, 
filled squares).  The wildtype, W170S and H109A mutant receptors all significantly differed from 
each other in their responses to zinc (see Figure 10 legend for statistics).  The addition of tricine 
to W170S receptors did not produce a significant change in W170S receptor modulation by -
hydroxybutyric acid (see Figure 10 legend for statistics).  The H109A mutant receptor converted 
-hydroxybutyric acid from a negative to a positive allosteric modulator and this showed some 
dependence on zinc (Figure 10D). 
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Figure 10.  -hydroxybutyric acid is a negative modulator of the 1 glycine receptor.   
A.  -hydroxybutyric acid inhibits the effects of the glycine EC5-10 in a concentration-dependent 
manner (solid circles).  Chelation of zinc using 10mM tricine had no overall significant effect on 
receptor potentiation by -hydroxybutyric acid (hollow circles) [F(1,49)=15.57, p<0.001]  B.  
Mutations in the 1 glycine receptor variably affect its responses to increasing zinc concentrations.  
The 1 wildtype receptor exhibits a biphasic response to zinc (solid circles), exhibiting 
enhancement at low M zinc concentrations and inhibition as the zinc concentration is increased.  
The H109A mutation is less sensitive to the inhibitory effects of zinc (solid squares), while the 
W170S mutation renders the receptor insensitive to the potentiating effects of zinc (solid triangles).  
C.  The W170S receptor retained sensitivity to the inhibiting effects of -hydroxybutyric acid, the 
effect of which was unaffected by the addition of the zinc chelator tricine (hollow triangles) 
[F(1,11)=1.76, p>0.21].  D.  -hydroxybutyric acid is a positive modulator at the H109A 1 
glycine receptor.  Increasing concentrations of -hydroxybutyric acid were co-applied with a 
glycine EC5-10 in the absence (solid squares) and presence (hollow squares) of 10mM tricine. There 
is a significant difference in the effect of -hydroxybutyric acid in the presence of tricine (ANOVA 
[F(1,8)=31.49, p<0.001]).  Each symbol represents data obtained from 3-8 oocytes from at least 2 
frogs, ± the standard error of the mean. 
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2.3.7 INVESTIGATING ZINC CONTAMINATION IN ACETONE AND -HYDROXYBUTYRIC ACID 
STOCKS USING ICP-MS  
ICP-MS measurements revealed that a control polypropylene tube containing 2% HNO3 
and ultrapure water had zinc levels (± standard deviation) of 3.275±0.086 ppb, 1mM -
hydroxybutyric acid contained 3.455±0.019 ppb, and 10mM acetone contained 3.258±0.071.  This 
correlates to approximately 50nM zinc present in distilled water in polypropylene tubes, with no 
further contamination in acetone. However, the tube containing 1mM -hydroxybutyric acid 
contained approximately 3nM of additional zinc.  These zinc concentrations could be high enough 
to explain, at least in part, the decreases in -hydroxybutyric acid effects seen in Figures 10A and 
10D in the presence of tricine. 
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2.4 Discussion 
The present study demonstrates that acetone and -hydroxybutyric acid affect NMDA, 
GABAA and glycine receptor function.  -hydroxybutyric acid modulates NMDA, GABAA and 
glycine receptors at physiologically-relevant concentrations. Typically, ketone body 
concentrations remain below 100 M but starvation can lead to plasma concentrations of 1mM 
acetone, while blood -hydroxybutyrate levels can exceed 5mM (Crandall, 1941; Mitchell et al., 
1998; Owen, 2006).  Brain concentrations of -hydroxybutyrate after just three days of fasting in 
humans have been reported to be approximately 1mM, and cerebrospinal fluid levels in children 
following a ketogenic diet are approximately 400M (Nordli and De Vivo, 1997; Pan et al., 2000).  
In patients suffering from diabetic ketoacidosis -hydroxybutyrate and acetone levels can total 
more than 25mM (Malchoff et al., 1984), most of which will be -hydroxybutyric acid.    
 
Concentrations of acetone greater than 10mM affected both NR1+NR2A and NR1+NR2B 
NMDA receptors (Figures 5A, 5B).  This modulation was independent of glutamate concentration, 
as acetone produced similar effects when applied with both high and low concentrations of 
glutamate.  This suggests that acetone acts as a non-competitive allosteric modulator at the NMDA 
receptor in a manner similar to alcohol (Peoples et al., 1997). -hydroxybutyric acid modulated 
NR2A- and NR2B-containing NMDA receptors to a similar extent, but unlike acetone the receptor 
modulation by -hydroxybutyric acid appeared to be somewhat dependent on glutamate 
concentration, with greater effects of -hydroxybutyric acid seen when it was applied with a high 
concentration of glutamate (Figures 5C and 5D).  This action is consistent with that of an 
uncompetitive antagonist, as also exemplified by memantine (Chen and Lipton 1997).  
Uncompetitive antagonists require prior receptor activation by a receptor agonist (in this case 
glutamate) before they can act.  In contrast to our results, Yang et al. (2007) reported no -
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hydroxybutyric acid modulation of NR1+NR2A NMDA receptors expressed in Xenopus oocytes, 
but they did not state what -hydroxybutyric acid concentrations they tested. 
 
The substitution of phenylalanine 639 with alanine in the NR1 subunit rendered the NMDA 
receptor less sensitive to ethanol (Figure 6A), consistent with previous findings (Ronald et al., 
2001).  This mutation also decreased the sensitivity of the NMDA receptor to both acetone (Figure 
6B) and -hydroxybutyric acid (Figure 6C), suggesting that this mutation is interfering with the 
actions of all three modulators.  It has been proposed that the F639 residue is important for the 
coupling of agonist binding to receptor opening, and other modulators of the NMDA receptor 
besides ethanol, such as isofluorane, xenon and chloroform also produce less inhibition in these 
mutant receptors, compared to wildtype (Ogata et al., 2006, Yang et al., 2007).  To investigate the 
possibility that acetone and/or -hydroxybutyric acid were competing with alcohol at the same site 
(i.e. some shared site involving the F639 residue), ethanol concentration-response curves were 
generated in the absence and presence of either acetone or -hydroxybutyric acid (Figure 7).  
Neither 30mM acetone nor 0.3mM -hydroxybutyric acid produced changes in the ethanol 
concentration-response curves in NR1 + NR2A or NR1 + NR2B receptors, suggesting that there 
was no competition for ethanol at these fixed concentrations of ketone bodies. If there was 
competition or synergy between ethanol and either of the ketone bodies we would hypothesize that 
at least one of the ethanol concentrations tested would be significantly different in the presence of 
a ketone.  The similar sensitivities to ethanol in the absence and presence of ketone bodies suggests 
that these compounds act additively with one another.  In addition, 30mM acetone did not 
significantly affect the degree of 0.1-3mM -hydroxybutyric acid inhibition of NMDA receptor 
function (Figure 7C).  
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Compounds that act additively with ethanol may be of therapeutic interest for the targeting 
of alcohol dependence and/or withdrawal.  These compounds would be expected to make 
individuals more susceptible to the effects of alcohol at lower concentrations, thus potentially 
decreasing the number of drinks they consume. Additionally, since acetone and ketone produce 
similar degrees of inhibition of the NMDA receptor as alcohol, switching alcoholics to a ketogenic 
diet while they withdraw from alcohol may help alleviate withdrawal symptoms.  Rodents fed a 
ketogenic diet while consuming alcohol for six days exhibited milder alcohol withdrawal 
symptoms compared to rodents fed a regular diet (Dencker et al., 2018).  It would be of interest to 
determine the magnitude of withdrawal symptoms in humans and rodents administered a ketogenic 
diet only after alcohol withdrawal, not before as well as after as modeled by Dencker et al. (2018), 
as a type of substitution therapy.  The National Institute on Alcohol Abuse and Alcoholism is 
currently conducting such a three-year clinical trial (Clinical trials gov identifier NCT03255031) 
in 100 participants assessing the benefits of the ketogenic diet following alcohol withdrawal.  
 
Acetone also acts in a manner similar to alcohol on GABAA and glycine receptors.  High, 
non-physiological (>100mM) concentrations of acetone positively modified GABAA and glycine 
receptors, with GABAA receptors showing greater effects of 1M acetone than glycine receptors 
(Figures 8A and 9A).  Our findings contrast with those of Yang et al. (2007) who reported that 
acetone was a potent positive modulator of homomeric 1 glycine receptors (at concentrations 
higher than 50M), and to a lesser degree also of 122s GABAA receptors (at concentrations 
exceeding 50mM).  The Yang et al., (2007) study found that acetone modulation of the glycine 
receptor peaked at 2.5mM acetone, with higher concentrations higher resulting in smaller effects; 
acetone exhibited an inverted U-shaped concentration response curve.  The acetone concentration-
response curve shown in Yang et al. (2007) is reminiscent of the zinc concentration-response curve 
seen in glycine receptors, where low zinc concentrations positively modulate the receptor by 
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binding to a zinc potentiation site, while higher zinc concentrations occupy a lower affinity zinc 
inhibitory site, resulting in decreased receptor potentiation and ultimately receptor inhibition (as 
shown in Figure 10B, filled circles).  One possibility is that in the Yang et al. (2007) study there 
may have been sufficient zinc contamination in the acetone stock or glassware to produce the data 
observed.  A previous study in our lab showed that zinc contamination may be a common 
occurrence (Cornelison and Mihic, 2014).  
 
To test if the modulatory effect of acetone on glycine receptors that we observed might be 
the result of contaminating zinc, or if acetone acted on the glycine receptor in a zinc-dependent 
manner, we tested the effects of 1M acetone on wildtype glycine receptors in the presence of a 
zinc chelator, tricine, and on mutant W170S 1 glycine receptors in which amino acid tryptophan 
170 was changed to serine (Figure 9A).  The presence of tricine did not alter acetone enhancement 
of the glycine receptor, suggesting that there was little to no zinc contamination present in our 
acetone stock, and that acetone actions on the glycine receptor are not zinc dependent, similar to 
volatile anesthetics (McCracken et al., 2010).  This contrasts with other modulators of the glycine 
receptor, such as alcohol and inhalants such as trichloroethane, which are influenced by zinc 
(McCracken et al., 2010; Cornelison et al., 2017).  The W170S glycine receptor mutant is 
insensitive to the potentiating effects of zinc (Figure 10B, filled triangles), as previous studies 
have described (Cornelison et al., 2017; Zhou et al., 2013).  If the acetone stock solution used in 
our studies had zinc contamination, or acted in a zinc-dependent manner, one would expect to see 
decreased effects of acetone on the W170S receptor. However, acetone produced a similar 
modulatory effect in W170S receptors as in wildtype receptors (Figure 9A), suggesting that the 
acetone effects observed on wildtype glycine receptors are not the result of contaminating zinc, 
nor are they zinc dependent.  ICP-MS results confirmed that there was no zinc contamination in 
our acetone stock.  Interestingly, the effects of acetone appeared to be dependent on the amino acid 
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present at position 267 of the glycine receptor (Figure 9B).  This is similar to how amino acid size 
at position 267 affects ethanol potentiation and is unsurprising given the similarity in structure 
between acetone and alcohol; the replacement of acetone's carbonyl group with a carboxyl group 
would yield isopropyl alcohol (Ye et al., 1998).  
 
-hydroxybutyric acid concentrations greater than 100M inhibited the effects of GABA 
on GABAA receptors (Figure 8C), while concentrations over 1mM negatively affected glycine 
receptor function (Figure 10A).  This is also in contrast to the Yang et al. (2007) study, which 
found that -hydroxybutyric acid positively modified glycine receptors at -hydroxybutyric acid 
concentrations greater than 3mM and produced around 14% enhancement of GABAA receptors at 
a -hydroxybutyric acid concentration of 20mM.  The effects of -hydroxybutyric acid on glycine 
receptors seen by Yang et al. (2007) might also be attributed to zinc contamination, but we are 
unable to speculate why they saw no inhibition with -hydroxybutyric acid, as high levels of 
contaminating zinc would inhibit, not potentiate, GABAA receptors.  While our ICP-MS results 
suggest a small amount of zinc contamination in our -hydroxybutyric acid stock solution, zinc 
chelation by tricine resulted in a greater inhibitory effect of the glycine receptor current by -
hydroxybutyric acid (Figure 10A).  This result was not unexpected, as low levels of contaminating 
zinc would tend to potentiate at the glycine receptor.   
 
The positive modulation by acetone, and negative modulation by -hydroxybutyric acid on 
glycine and GABAA receptors appears to be dependent on agonist (GABA or glycine) 
concentration, with acetone and -hydroxybutyric acid having modulatory effects only at low 
concentrations of agonist (Figure 8B, 8D, glycine data not shown).  This is similar to other 
modulators of these receptors, such as benzodiazepines on GABAA receptors and zinc or ethanol 
on glycine receptors (Newland et al.,1991; Farley and Mihic, 2015). 
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To our knowledge, this is the first report that -hydroxybutyric acid negatively modulates 
NMDA, GABAA and glycine receptors at pharmacologically-relevant concentrations.  If -
hydroxybutyric acid inhibits both excitatory and inhibitory neurotransmission, one might surmise 
that the two effects could cancel each other out in vivo, thus questioning the clinical relevance of 
our findings.  However, we found greater percent effects of -hydroxybutyric acid on NMDA than 
GABAA and glycine receptors (compare Figures 5, 8 and 10).  Thus, although antagonism of 
agonist effects on inhibitory neurotransmitter receptors would to some extent counteract the -
hydroxybutyric acid inhibition observed at NMDA receptors, this agent appears more efficacious 
at the latter.  It should also be pointed out that even if percent inhibition by -hydroxybutyric acid 
was the same in GABAA and NMDA receptors, this does not mean that the two effects would 
necessarily cancel each other out.  Also playing roles would be the relative numbers of each 
receptor type on individual neurons, how quickly the receptors desensitized, how often they were 
activated relative to one another, and what their relative unitary conductances were, among other 
factors.  None of the receptors tested responded to physiological concentrations (1mM) of acetone, 
but NMDA receptors had the lowest threshold (10mM) for acetone effects of the receptors tested. 
The lack of clinical data describing acetone concentrations achieved in the brain during 
ketogenesis may account for a lower physiological acetone concentration reported than what truly 
occurs.  We hypothesize that ketogenesis can yield -hydroxybutyric acid, but not acetone, 
concentrations in vivo sufficient to modulate NMDA, GABAA and glycine receptor function, and 
that this receptor modulation may account in part for the therapeutic effects seen with a ketogenic 
diet. 
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CHAPTER 3: AN INTER-SUBUNIT ELECTROSTATIC INTERACTION 
IN THE GABAA RECEPTOR FACILITATES ITS RESPONSES TO 
BENZODIAZEPINES2 
 
3.1 Introduction 
Inter- and intra-subunit electrostatic interactions play important roles in cys-loop receptor 
function.  For example, electrostatic interactions between residues of adjacent alpha subunits in 
the glycine receptor play an important role in its activation (Todorovic et al., 2010).   Specifically, 
the aspartate 97 residue is thought to interact with arginine 119 to stabilize the closed state of the 
glycine receptor, and once this bond is broken after agonist binding, the channel opens.  
Additionally, electrostatic interactions between aspartic acid 149 and lysine 279 within the same 
 subunit, as well as between aspartic acid 146 and lysine 215 within the same  subunit are 
implicated in the coupling of GABA binding to the opening of the GABAA receptor (Kash et al., 
2003; Kash et al., 2004).   Further, glutamic acid 153 and lysine 196 within the same  subunit of 
the GABAA receptor may be involved in stabilizing the open state of the receptor (Venkatachalan 
and Czajkowski, 2008).  Disulfide trapping experiments have led to insights into the 
conformational changes that benzodiazepines produce in the GABAA receptor after binding; 
however, thus far an electrostatic interaction has not been identified in the GABAA receptor that 
occurs because of this conformational change (Hanson and Czajkowski, 2011).  
 
 
                                                 
2 This chapter details work that has been published. Pflanz N.C. was responsible for the design, conduction and 
analysis of these experiments and for writing the manuscript. 
 Pflanz N.C., Daskowzski A.W., Cornelison G.C., Trudell, J.R., Mihic S.J. An inter-subunit electrostatic interaction in the GABAA receptor 
facilitates its responses to benzodiazepines (2018) Journal for Biological Chemistry. 293: 8264-8274. 
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In the current chapter, we used homology modeling with published structures to produce 
models of 122 GABAA receptor.  We used these models to identify potential electrostatic 
interactions occurring before or after the conformational changes produced by benzodiazepine 
binding, identifying a pair of residues that appear to be interacting in a manner specific for 
benzodiazepine modulation of the GABAA receptor. 
3.2 Methods 
 
3.2.1 REAGENTS 
All chemicals were purchased from Sigma-Aldrich (St. Louis, MO) unless otherwise stated 
below. 
 
3.2.2 STRUCTURAL MODELING  
Two homology models of the GABAA receptor were generated using the Modeler module 
of Discovery Studio 2016 (DS 2016, Biovia, San Diego, CA) as previously described (McCracken 
et al., 2016).  The first model was of the GABAA receptor in the benzodiazepine-unbound state.  
This was built using the GluCl X-ray structure in the absence of ivermectin as a template (Yoluk 
et al., 2013).  This template was produced by starting with the structure of GABAA receptor with 
five ivermectin molecules bound (PDB ID 3RHW), removing the five ivermectin molecules, and 
then running extensive constrained molecular dynamics simulations using GROMACS 4.5.  The 
resulting model was judged to be in the closed/resting state because the subunits moved closer by 
2.0 Å and the pore diameter decreased by 1.2 Å (Yoluk et al., 2013).  The second homology model 
illustrated the GABAA receptor after diazepam was bound.  This model was based on a 
GluCl/ELIC X-ray structure which modeled diazepam binding (Bergmann et al., 2013).   It should 
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be noted that other investigators have proposed a different orientation of diazepam docking at this 
/ interface (Ci et al., 2008).  The latter model is based primarily on the glutamate-bound GluCl 
crystal structure (PDB ID 3RIF) with a contribution of the ELIC crystal structure (PDB ID 2VLO). 
Of interest for the present results; in GABAA receptor  lysine 104 is in beta strand 4 and all 
coordinates are from GluCl.  However, in GABAA receptor 2, aspartic acid 75 is in beta strand 2, 
a residue that is conserved in ELIC but not in GluCl, As a result, the investigators used the ELIC 
structure as a template for residues 75-77 (Bergmann et al., 2013). 
 
Since both templates are homopentamers and our goal was to measure intersubunit 
interactions, we prepared a composite sequence by linking GABAA receptor 1/2/1/2/2 and 
aligning the composite with the sequence of the two templates (Trudell, 2002).  Then the GABAA 
receptor sequences were trimmed to match the length of the template sequences as needed.  The 
two pairs of aligned sequences were submitted to the Modeler module of DS 2016. 
 
Both of the resulting homology models were assigned the CHARMM force field in DS 
2016, minimized, and then subjected to molecular dynamics simulations at 300K as previously 
described (McCracken et al., 2016).  These two models were analyzed for possible electrostatic 
interactions using DS 2016. 
  
3.2.3 SITE-DIRECTED MUTAGENESIS 
Human cDNAs encoding 1, 2 and 2 GABAA receptor subunits, subcloned into a pBK-
CMV vector, were used in this study.  Point mutations were introduced in the 1 and 2 subunits 
using a QuikChange site-directed mutagenesis kit (Agilent Technologies, CA).  These mutations 
were confirmed with double-stranded DNA sequencing. 
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3.2.4 TWO-ELECTRODE VOLTAGE CLAMP ELECTROPHYSIOLOGY 
Oocytes were harvested and injected as described in Chapter two. Oocytes expressed 
GABAA receptors 1-3 days post injection with cDNA, and all electrophysiological recordings were 
completed within this time.  An oocyte was placed in a 100L bath containing ND-96 buffer and 
continuously perfused at a rate of 2ml/minute, as described in chapter two. 
 
3.2.5 CONCENTRATION-RESPONSE CURVE GENERATION AND ANALYSIS 
Concentration-response data were collected for wildtype 122 GABAA receptor or the 
1(K104C)22, 1(K104A)22, 122(D75C), 122(D75A), 1(K104C)22(D75C), 
1(K104A)22(D75A) or 1(K104D)22(D75K) mutants.  Once voltage clamped, the oocyte was 
exposed to a maximally-effective concentration of GABA (100mM) for 10 sec.  Following a ten-
min washout with ND-96 buffer to allow re-sensitization of the receptors, increasing 
concentrations of GABA (3M-10mM) were applied for 20-30 seconds, allowing 5-10 minutes of 
washout between applications. Another maximally-effective concentration of GABA (100mM) 
was applied at the end of the experiment, so that any drift (up or down) of current throughout the 
experiment could be corrected for. The responses to increasing concentrations of GABA were fit 
to the Hill equation using SigmaPlot 11.0 (Systat Software, CA).  
 
3.2.6 GABAA RECEPTOR MODULATOR RESPONSES 
Responses to modulators (1µM diazepam, 1µM flunitrazepam, 1µM flumazenil, 1µM Ro 
15-4513, 1µM zolpidem, 100nM and 1µM allopregnanolone, 200mM ethanol) were recorded in 
oocytes expressing wildtype or mutant receptors.  10mM stock solutions of all modulators (made 
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with 0.1% DMSO in ND-96 buffer), except ethanol, were stored at -20C and diluted in ND-96 
before use. 
 
The GABA EC5-10, the concentration of GABA that produces 5-10% of the maximal 
response, was first determined and then repeatedly applied for 30 seconds, followed by 3 minute 
ND-96 washouts, until responses were stable.  Once stable, oocytes were pre-incubated for 30 
seconds with a modulator, followed immediately by a co-application of modulator plus GABA 
EC5-10.  The allosteric modulation was calculated as [(IGABA + Modulator/IGABA)-1] *100. 
 
3.2.7 DITHIOTHREITOL (DTT) AND HYDROGEN PEROXIDE (H2O2) TREATMENT 
DTT and H2O2 were made fresh in ND-96 buffer before each experiment.  The GABA EC5-
10 was determined and applied at three minute intervals until stable responses were obtained.  This 
was repeated after a 2 minute DTT (2mM) application, during which the oocyte was unclamped 
from -80 mV, and given a subsequent 5 minute ND96 washout, and after a 90 second application 
of 0.3% H2O2 (7 minute washout after, oocyte also unclamped).  To measure the effects of DTT 
and H2O2 on allosteric modulation, the GABA EC5-10 was determined and ensured to be stable.   
GABA was then applied in the presence of an allosteric modulator, as described previously.  
 
3.2.8 PROPYL METHANETHIOSULFONATE (PMTS) TREATMENT 
A 300mM PMTS (Toronto Research Chemicals, Canada) stock solution in DMSO was 
stored at -20°C and diluted to 0.5mM in ND-96 before each experiment.  The GABA EC5-10 was 
determined and applied at 3 minute intervals until stable responses were observed.  Oocytes were 
then unclamped from -80mV and treated with 0.5mM PMTS for 60 seconds.  After a 2 minute 
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wash, oocytes were re-clamped to -80 mV and the same GABA EC5-10 was reapplied.  Percent 
changes in current were calculated as [(IGABA after PMTS/IGABA before PMTS)-1] *100.  This was repeated 
after a 2 minute treatment with 2mM DTT, waiting 5 or 60 minutes after application before 
applying PMTS. 
 
3.3 Results 
3.3.1 MOLECULAR MODELING IDENTIFIES POSSIBLE ELECTROSTATIC INTERACTIONS PRESENT 
BEFORE AND AFTER BENZODIAZEPINE BINDING AT THE 1-2 SUBUNIT INTERFACE OF THE 
GABAA RECEPTOR. 
As a starting point for our studies, we used two different models to identify potential 
electrostatic interactions at the 1-2 subunit interface.  The first was based on molecular dynamic 
modeling performed by Yoluk et al. (2013) on the GluCl ligand-gated cys-loop receptor, in the 
absence of ivermectin (Figure 11, left).  This first model corresponds to the closed, GABA- and 
benzodiazepine-unbound state of the GABAA receptor in our studies.  The second model (Figure 
11, right) is based on the GABA- and diazepam-bound GABAA receptor model described by 
Bergmann et al. (2013).  Choosing to investigate only charged residues predicted to be 6Å or less 
apart, we identified seven interactions that could occur before benzodiazepine binding, as well as 
four interactions that could occur after benzodiazepine binding.  Two of these pairs, aspartic acid 
56 of the 1 subunit (1D56) with arginine (R) 197 of the 2 subunit (2R197), as well as glutamic 
acid (E) 58 of the 1 subunit (1E58) with 2R197, were predicted to form electrostatic pairs both 
before and after diazepam binding.  In the present study, we focused on the electrostatic 
interactions that were predicted to interact closest to the benzodiazepine binding site (Figure 11, 
interactions B-F and H-K). 
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Figure 11. Two different homology models of the 1 (orange) - 2 (green) interface of the 
GABAA receptor. 
The model on the left is based on a modified ivermectin-unbound GluCl crystal structure and 
represents the GABA-unbound closed state of the channel (Yoluk et al., 2013).  The model on the 
right is based on the glutamate-bound GluCl crystal structure with a contribution of the ELIC 
crystal structure and represents the diazepam (in red) bound receptor (Bergmann et al., 2013).  
Both models depict the inside of the interface.  Labeled interactions represent putative electrostatic 
interactions of residues 6Å or less apart that are predicted to occur between residues in the 1 and 
2 subunits before (A-F) or after (H-K) diazepam binding. A: 1R28-2D26; 5Å. B: 1E165-2R97; 
4Å. C: 1E137-2R194; 5Å. D: 1E58-2R197; 5Å. E: 1D56-2R197; 5Å. F: 1K278-2D161; 
5Å. G: 1K311-2D260; 3Å. H: 1K105-2D120; 5Å. I: 1K104-2D75; 5Å. J: 1E58-2R197; 
5Å. K: 1D56-2R197; 6Å.   Black dashed lines represent inter-subunit bonds.  
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3.3.2 EFFECTS OF CYSTEINE SUBSTITUTION ON DIAZEPAM POTENTIATION OF GABAA 
RECEPTOR FUNCTION 
Diazepam (1M) enhancement of the effects of a GABA concentration required to produce 
5-10% of the maximal response (EC5-10), was tested on a series of cysteine mutants.  Cysteine 
substitution of residues of the 1 or 2 subunit predicted to be involved in electrostatic interactions 
before and/or after diazepam binding resulted in a significant effect of mutation on diazepam 
potentiation (see Figure 12 legend for statistics). Replacing 1 E58 with cysteine [1(E58C)] 
resulted in a significant increase in diazepam potentiation, while the 1(K104C), 1(E137C), 
2(D75C) and 2(R197C) substitutions all resulted in significant decreases in diazepam 
enhancement (Figure 12).  Six of the other residues substituted with cysteine, 1(D56C), 
1(K105C), 1(E165C), 2(R97C), 2(D120C) and 2(R194C), resulted in no significant changes 
in receptor enhancement by diazepam, compared to wildtype GABAA receptor.  Of the pairs 
probed, the only hypothesized pair that produced similar changes in diazepam effects upon 
mutation to cysteine were 1(K104C) and 2(D75C) (Figure 11, interaction I). If an electrostatic 
interaction was occurring between two residues, one would expect similar changes in receptor 
function if that bond was broken by mutating either residue.  For this reason we focused on the 
1K104 - 2D75 pair. Before diazepam binding 1K104 was predicted to be approximately 9Å 
from 2D75 (Figures 13A and 13B), but after diazepam binding these residues were predicted to 
move much closer together, to approximately 5Å apart (Figure 13C). 
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Figure 12. Diazepam enhancement of GABAA receptor function is altered in some cysteine 
mutations of residues predicted to form electrostatic interactions at the 1-2 subunit 
interface. 
EC5-10 GABA was applied alone, as well as in the presence of 1M diazepam, to wildtype and 
multiple cysteine substituted receptors.  The horizontal dashed line indicates the level of 
potentiation produced by diazepam in wildtype receptors.  A one-way ANOVA showed a 
significant effect of cysteine substitution on receptor enhancement by 1µM diazepam, 
[F(11,60)=26.310, p<0.001].  A post-hoc Tukey’s test showed a significant change (p<0.001) in 
potentiation by 1µM diazepam in 1E58C, 1K104C, 1E137C, 2D75C and 2R197C containing 
GABAA receptor.  Each symbol represents the percent potentiation of the GABA EC5-10 by one 
oocyte, and each bar represents the mean percent potentiation ± SEM. 
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Figure 13. Homology models of the 1 (orange) - 2 (green) interface inside the GABAA 
receptor in both the GABA-unbound closed state of the channel and the diazepam-bound 
open state of the channel.   
These models predict that the nitrogen atom of 1 lysine 104 (orange residue) and oxygen atom of 
2 aspartic acid 75 (green residue) are within 9Å of each other before GABA and diazepam bind 
(A and enlarged in B) but move to within 5Å of each other after GABA and diazepam (in red) bind 
to the receptor (C).  
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3.3.3 EFFECTS OF CYSTEINE SUBSTITUTION ON GABA SENSITIVITY AT 1K104 AND 2D75 
RESIDUES 
GABA concentration-response curves for 1(K104C)22, 122(D75C) and 
1(K104C)22(D75C) receptors did not significantly differ from those of wildtype receptors 
(Figure 14A).  However, one-way ANOVAs revealed that lower GABA concentrations (3M and 
10M) produced greater responses in 1(K104C)22(D75C) receptors compared to the single 
mutants and wildtype receptors (see Figure 14 legend for statistics).  Despite the model-based 
hypothesis that the electrostatic interaction between 1K104 and 2D75 is predicted to occur after 
diazepam binding, substituting these residues with cysteines could allow a disulfide bond to form 
spontaneously, which would be able to form between residues at greater distances apart than an 
electrostatic bond.  Therefore, we tested if the disulfide bond between 1K104C and 2D75C had 
spontaneously occurred.  The reducing agent dithiothreitol (DTT) is able to break accessible 
disulfide bonds.  Application of 2mM DTT to the 1(K104C)22(D75C) receptor resulted in an 
increase in the GABA EC5, from 3.6 ± 0.4 M before DTT application to 10.5 ± 0.35M after 
DTT (Figure 14B).  This is due to the breakage of a single inter-subunit disulfide bond as shown 
in Figure 15A. 
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Figure 14. Formation and breakage of the disulfide bond between 1(K104C) and 2(D75C) 
affects responses to GABA.  
 A. GABA concentration-response curves were generated in wildtype 122, single mutant 
1(K104C)22 and 122(D75C), and double mutant 1(K104C)22(D75C) GABAA receptors.  
A repeated-measures ANOVA revealed no difference in the concentration-response curve between 
wildtype and mutant receptors.  However, one-way ANOVAs showed significant effects of 
mutation at 3 µM [F(3,26)=15.504, p<0.001] and 10 µM GABA [F(3,26)=18.163, p<0.001], with 
a Tukey’s post-hoc test at both concentrations showing a significant increase in response in 
1(K104C)22(D75C) receptors compared to the other three receptors (***, p<0.001).  Some 
symbols are hidden behind other symbols.  B. DTT (2 mM, dark symbols and bars) increased the 
absolute concentration of GABA required to produce an EC5 response in 1(K104C)22(D75C) 
but not wildtype receptors.  A two-way ANOVA followed by a Tukey’s post-hoc test revealed a 
significant effect of DTT treatment on 1(K104C)22(D75C) receptors (***, p<0.001).  Each 
symbol represents the GABA EC5 of one oocyte, and each bar represents the mean GABA EC5 ± 
SEM. 
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To further probe if 1K104C and 2D75C spontaneously form a disulfide bond in the 
1(K104C)22(D75C) receptor, we tested PMTS for its effects.  PMTS is able to covalently bind 
to free cysteine residues to which it has access. PMTS caused a significant decrease in GABA EC5 
current in the single and double mutant receptors (Figure 15B, hollow bars with open circles).  In 
the wildtype and both single cysteine mutant receptors, the effect of PMTS remained unchanged 
after a prior DTT application (Figure 15B, hollow bars with triangles).  This indicates that in 
single mutant receptors the cysteine substituted residues do not form disulfide bonds with 
endogenous cysteines in GABAA receptor.  Since these single mutant and wildtype receptors 
exhibited similar changes in response to PMTS before and after DTT application, we did not test 
these receptors again 60 minutes after DTT treatment. For the 1(K104C)22(D75C) receptor, a 
one-way ANOVA revealed a significant effect of PMTS treatment before, 5 minutes after, and 60 
minutes after DTT treatment [F(2,13)=108.363, p<0.001]. Without prior exposure to DTT, 
application of PMTS resulted in a decrease in current (Figure 15B, white bar, open circles). 
However, DTT application before PMTS resulted in an increase in current (solid bar).  Waiting 60 
minutes after DTT washout, and then applying PMTS, resulted in a decrease in current similar to 
that seen with PMTS application before DTT application.  For the double cysteine mutant receptor 
the white bar with open circles represents PMTS binding to the single available cysteine residue 
situated between the  and  subunit interfaces as shown in the illustration on the left in Figure 
15A.  When DTT breaks the sole disulfide bond between  and  subunits, PMTS can now bind 
to up to three free cysteines.  Since there was no significant difference between PMTS application 
before DTT application and 60 minutes after DTT application, we hypothesize that the disulfide 
bond breakage produced by DTT is only temporary, and that the receptor spontaneously returns to 
its pre-DTT form within an hour. The reformation of the disulfide bond in the double mutant 
receptor was also seen experimentally by repeatedly applying the GABA EC5 to the DTT-treated 
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receptor and observing a gradual increase in current (Figures 15C and 15D).  The current 
produced by a maximally-effective concentration of GABA was not changed by applying DTT. 
  
 71 
 
 
 
 
 
 
 
 
Figure 15. α1(K104C)β2γ2(D75C) receptors spontaneously crosslink, and reform this 
crosslink after DTT application.   
A. Illustration depicting the disulfide bond that spontaneously crosslinks between the α1 and γ2 
subunits of the α1(K104C)β2γ2(D75C) GABAA receptor, and that is broken after DTT application, 
slowly reforming over time.  B. Effect of PMTS application on currents elicited by the GABA 
EC5-10 of wildtype, 1(K104C)22, 122(D75C) and 1(K104C)22(D75C) GABAA receptors.  
The change in GABA EC5-10 currents by PMTS was decreased in single mutant receptors both 
before [F(3,18) = 14.56, p <0.05] and after [F(3,18) = 45.45, p <0.001] DTT application compared 
to those seen in wildtype receptors.  The change in EC5-10 currents produced by PMTS was not 
significantly altered after DTT application to wildtype or single mutant receptors, but did 
significantly change in double mutant receptors [F(3,37)=41.698, p<0.001)].  A one-way ANOVA 
showed a significant effect of time after DTT treatment (pre-DTT treatment, 5 minutes after and 
60 minutes after) on 1(K104C)22(D75C) GABAA receptor [F(2,13)=108.363, p<0.001], and a 
Tukey’s post-hoc test showed a significant difference between pre-DTT and 5 minutes after DTT 
application and a significant difference between 5 minutes after DTT and 60 minutes after DTT 
(***, p<0.001; each symbol represents an oocyte, and bars represent the mean ± SEM).  C. Sample 
tracing showing spontaneous re-formation of the 1-2 inter-subunit disulfide bond in the 
1(K104C)22(D75C) GABAA receptor.  The GABA EC5 measured in the oocyte before DTT 
application was 3µM GABA, but after DTT application 3µM GABA elicited a much smaller 
response. After approximately 60 minutes the response to 3µM GABA had returned to pre-DTT 
levels.  D. Time courses of EC5 values plotted for 5 oocytes expressing 1(K104C)22(D75C) 
receptors returning to their pre-DTT values.  This can also be interpreted as the time required to 
re-form the disulfide bond after DTT application.  The average time to return to half of the pre-
DTT EC5 was 26.9 ± 2.5 minutes. 
 72 
3.3.4 EFFECT OF CYSTEINE SUBSTITUTION AT 1K104 AND 2D75 ON BENZODIAZEPINE-SITE 
RESPONSES 
There were no effects of DTT application on the modulation produced by 1M diazepam, 
flunitrazepam, Ro 15-4513 or zolpidem on wildtype receptors, as expected.  This was also the case 
for 1(K104C)22 and 122(D75C) receptors.  However, application of DTT to the 
1(K104C)22(D75C) receptor produced an increase in diazepam potentiation (from 76.6 ± 6.3% 
to 136.7 ± 9%) and flunitrazepam potentiation (from 121.2 ± 9.1% to 201 ± 22.3%), and a decrease 
in potentiation by Ro 15-4513 (from 1 ± 3.2 to -17.8 ± 1.9%) (Figure 16A-C).   DTT treatment 
rescued responses of 1(K104C)22(D75C) receptors to wildtype levels by flunitrazepam and Ro 
15-4513, but not by diazepam.  Application of the non-classical benzodiazepine, zolpidem, did not 
produce a significant interaction between receptor mutant and DTT treatment, but a Tukey’s post-
hoc test revealed a small significant difference between pre- and post-DTT treatment in 
1(K104C)22(D75C) receptors (p<0.05) (Figure 16D).  Interestingly, Ro 15-4513 produced a 
greater inhibitory response in the 122(D75C) mutant compared to wildtype receptors, both 
before and after DTT treatment (Figure 16C).  Treatment with 0.3% H2O2 for 90 seconds, which 
would favor cysteine bond reformation, before the benzodiazepine application reversed the effects 
of DTT in 1(K104C)22(D75C) receptors, but produced no changes in responses by wildtype 
receptors (Figures 17A and 17B).  
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Figure 16.  Benzodiazepine responses of wildtype and mutant GABAA receptors before 
(white symbols and bars) and after (dark symbols and bars) DTT application.   
Bar graphs showing the percent potentiation of GABA EC5-10 in wildtype, 1(K104C)22, 
122(D75C) and 1(K104C)22(D75C) GABAA receptors produced by 1µM (A) diazepam, (B) 
flunitrazepam, (C) Ro 15-4513, and (D) zolpidem.  A two-way ANOVA followed by a Tukey’s 
multiple comparison post-hoc test showed a significant increase in all benzodiazepine-site 
responses after DTT application to 1(K104C)22(D75C) GABAA receptors but not wildtype or 
single mutant receptors (*, p<0.05; ***, p<0.001, with each symbol representing the percent 
potentiation of the GABA EC5-10 seen in one oocyte, and each bar representing the mean percent 
potentiation ± SEM). 
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Figure 17. Sample tracings showing the effects of DTT and H2O2 treatment on potentiation 
by 1µM diazepam and 1µM flunitrazepam.  
The top panels show tracings obtained from oocytes expressing wildtype receptors while the 
bottom panel shows tracings of oocytes expressing 1(K104C)22(D75C) GABAA receptors. 
DTT application to 1(K104C)22(D75C) receptors increased both diazepam (A) and 
flunitrazepam (B) potentiation, and hydrogen peroxide application reversed this increase back to 
pre-DTT levels. 
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3.3.5 EFFECTS OF CYSTEINE SUBSTITUTION ON NON-BENZODIAZEPINE MODULATORS OF THE 
GABAA RECEPTOR 
Allosteric modulators of the GABAA receptor acting at sites other than the benzodiazepine 
binding site were next tested to determine the specificity of the electrostatic interactions between 
1(K104C) and 2(D75C).  Ethanol and the neurosteroid allopregnanolone produced similar 
potentiation of the effects of GABA on wildtype, 1(K104C)22, 122(D75C) and 
1(K104C)22(D75C) GABAA receptors (Figure 18).  There was no significant effect of DTT 
treatment on the enhancement of wildtype or mutant receptors by 200mM ethanol, 100nM 
allopregnanolone (Figure 18) or 1M allopregnanolone (data not shown).   
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Figure 18.  Modulators acting at sites other than the benzodiazepine site at wildtype and 
cysteine substituted GABAA receptors are unaffected by DTT treatment.   
Before modulator effects were tested, the EC5-10 concentration of GABA was determined in each 
oocyte.  Effects of 200mM ethanol and 100nM allopregnanolone were measured in wildtype and 
1(K104C)22(D75C) GABAA receptors before (white symbols and bars) and after (dark symbols 
and bars) application of DTT, with no significant changes being observed (Two-way ANOVA’s: 
200mM ethanol [F(3,43)=0.031]; 100nM Allopregnanolone [F(3,45)=0.176]. Each symbol 
represents the percent potentiation of the GABA EC5-10 seen in one oocyte, and each bar represents 
the mean percent potentiation ± SEM.  
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3.3.6 EFFECTS OF ALANINE SUBSTITUTION AT 1K104 AND 2D75 ON GABA AND 
BENZODIAZEPINE RESPONSES 
To examine the effects of alanine substitutions at the 1K104 and/or 2D75 residues, we compared 
receptors containing these alanine residues to wildtype receptors in their responses to GABA, 1M 
diazepam and 1M flunitrazepam.  The GABA concentration-response curve for 122(D75A) 
was slightly right shifted (EC50 133.6 ± 19.4 M), while that of the 1(K104A)22 receptor was 
slightly left shifted (EC50 61.9 ± 12.2 M) compared to the wildtype receptor curve (EC50 77 ± 8.8 
M) (Figure 19A).  A repeated-measures ANOVA revealed a significant difference among the 
four concentration-response curves (see Figure 19A legend for statistics). Interestingly, the 
1(K104A)22(D75A) GABA concentration-response curve (EC50 87.3 ± 12.4 M) was not left-
shifted at lower concentrations (3M and 10M), unlike the 1(K104C)22(D75C) receptor 
(Figure 19A compared to Figure 14A).  One-way ANOVAs revealed that there was a significant 
effect of alanine substitution on the enhancement of GABA EC5-10 by 1M diazepam or 
flunitrazepam. While the single substitution 1(K104A)22 and 122(D75A) receptors exhibited 
a decreased response to diazepam and flunitrazepam compared to wildtype receptors, the 
1(K104A)22(D75A) receptors displayed a level of potentiation not significantly different from 
that of wildtype receptors (Figure 19B). 
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Figure 19. Effect of alanine substitution at 1K104 and 2D75 on GABA sensitivity and 
benzodiazepine responses.   
A. GABA concentration-response curves of wildtype, 1(K104A)22, 122(D75A), and 
1(K104A)22(D75A) receptors. The concentration-response curves were significantly different 
[F(21,132)=1.937, p<0.05].  Each symbol represents the data from 3-6 oocytes ± SEM.  In some 
cases error bars fall within symbols.  B. Bar graph comparing levels of diazepam and flunitrazepam 
potentiation between wildtype and alanine substituted receptors.  Potentiation of GABA EC5-10 by 
1µM diazepam and 1µM flunitrazepam was decreased for single but not double alanine 
substitution mutants compared to wildtype receptors.  A one way ANOVA revealed a significant 
effect of mutant on receptor potentiation by diazepam [F(3,23)=51.407, p<0.001] and 
flunitrazepam [F(3,19)=26.926, p<0.001].   Each symbol represents the percent potentiation 
observed in one oocyte, and each bar represents the mean percent potentiation ± SEM. 
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3.3.7 EFFECTS OF CHARGE REVERSAL OF 1K104 AND 2D75 RESIDUES ON GABA AND GABA 
RECEPTOR MODULATOR RESPONSES 
To test if reversing the charges of 1K104 and 2D75 would restore GABA sensitivity, GABA 
concentration-response curves of 1(K104D)22(D75K) were compared to those of wildtype 
receptors (Figure 20A).  A repeated-measures ANOVA found a significant difference between 
wildtype and 1(K104D)22(D75K) concentration response curves (see Figure 20A legend for 
statistics).  The average EC50 value for wildtype receptors was 86.8 ± 16.5 M while the EC50 for 
1(K104D)22(D75K) was increased to  146.3 ± 23.1 M.  The charge reversal did not restore to 
wildtype levels receptor potentiation by 1 M diazepam or Ro 15-4513, but did restore potentiation 
by 1 M flunitrazepam and zolpidem (Figure 20B).  Other GABAA receptor modulators (200 mM 
ethanol and 100 nM allopregnanolone) displayed no changes in potentiation of GABA EC5-10 after 
charge reversal, compared to wildtype receptors (data not shown). 
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Figure 20. Charge reversal at 1K104 and 2D75 does not rescue GABA sensitivity or 
benzodiazepine responses to wildtype responses.   
A. The 1(K104D)22(D75K) receptor GABA concentration-response curve is significantly 
right-shifted compared to wildtype receptors [F(8,105)=2.8, p<0.01]. The EC50 for wildtype 
receptors was 86.8 ± 16.5µM, increasing to 146.3 ± 23.1µM for the 1(K104D)22(D75K) 
GABAA receptor.  Each symbol represents the mean ± SEM from 5-6 oocytes.  B. Bar graph 
comparing levels of benzodiazepine enhancement between 1(K104D)22(D75K) and wildtype 
receptors. The 1(K104D)22(D75K) GABAA receptor was unable to fully rescue responses to 
wildtype levels of potentiation by 1µM diazepam and  Ro 15-4513, but was able to rescue the 
responses to 1µM flunitrazepam and zolpidem.  Each symbol represents the percent potentiation 
of the GABA EC5-10 seen in one oocyte, and each bar represents the mean potentiation ± SEM.  
  
 81 
3.4 Discussion 
Signal transduction of ligand-gated ion channels after neurotransmitter binding to its 
orthosteric site is believed to involve a wave of structural rearrangements  in the receptor, and this 
rearrangement is thought to be separate from the signal transduction pathway produced by 
allosteric modulators (Grosman et al., 2000; Venkatachalan and Czajkowski, 2012).  Using 
molecular modeling to identify potential electrostatic interactions between the 1 and 2 subunits, 
we identified an interaction between 1K104 and 2D75 that occurs after diazepam binding 
(Figure 13). It is likely that these residues interact to stabilize the positively-modified state of the 
receptor, and that this interaction is specific for the benzodiazepine signal transduction pathway.  
 
Low concentrations of GABA produced greater responses in 1(K104C)22(D75C) than 
in wildtype receptors, but this was not seen at higher GABA concentrations (Figure 14A). This 
increased response at low GABA concentrations is similar to what one would expect to see in 
response to co-application of GABA with a benzodiazepine in wildtype receptors.  Benzodiazepine 
site agonists increase the effects of low but not higher concentrations of GABA, since the ion 
channel approaches its maximal open probability at saturating GABA concentrations (Newland et 
al., 1991).  
 
One would predict that a receptor that is behaving as though a benzodiazepine molecule 
has already bound would exhibit a decreased response to a co-application of benzodiazepine with 
GABA.  In the 1(K104C)22(D75C) receptor, the two cysteine residues spontaneously formed a 
disulfide bond.  Accordingly, we saw the expected decrease in diazepam, flunitrazepam, and 
zolpidem potentiation in the double cysteine substituted receptors (Figures 16A, 16B and 16D).  
After the disulfide bond is broken with DTT, responses to these benzodiazepines increase, 
suggesting that an electrostatic bond between these residues in wildtype receptors formed in 
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response to benzodiazepine binding.  After DTT application, the response of 
1(K104C)22(D75C) receptors to flunitrazepam potentiation was rescued to wildtype levels 
(Figure 16B).  One reason why potentiation by flunitrazepam, but not diazepam or zolpidem, may 
be completely rescued following DTT application is that the latter two show weaker modulatory 
responses after 1K104C-2D75C disulfide bond formation than flunitrazepam; i.e., lower 
potentiation of GABA responses before DTT application. The conformational rearrangement 
within the GABAA receptor after benzodiazepine binding most likely depends on the formation of 
multiple bonds, not just 1K104-2D75.  Thus, the 1K104 - 2D75 bond may be less important 
for flunitrazepam potentiation than for diazepam or zolpidem.  
 
Zolpidem is a non-classical benzodiazepine and at low concentrations is selective for the 
1 subunit-containing GABAA receptor over those containing other α subunits (Langer et al., 
1992). Disulfide trapping within the 2 subunit has shown that the conformational change produced 
by classical benzodiazepines may not be the same as that produced by zolpidem (Hanson and 
Czajkowski, 2011). Similarly, there are mutations in the 1 and 2 subunits that affect classical but 
not non-classical benzodiazepines, or vice versa (Mihic et al., 1994; Buhr and Sigel, 1997; Bowser 
et al., 2002; Hanson and Czajkowski, 2008). The magnitude of the increase in 
1(K104C)22(D75C) receptor potentiation by zolpidem after DTT application was far smaller 
than the increase seen with the classical benzodiazepines diazepam and flunitrazepam (Figure 16).  
We speculate that this may be due to classical and non-classical benzodiazepines producing 
overlapping yet distinct conformational changes in the GABAA receptor after binding.  
 
One might hypothesize that the conformational changes produced by benzodiazepines 
would be different than those produced by inverse agonists such as Ro 15-4513. Indeed, previous 
studies have shown that this might be the case, where disulfide trapping at the α-γ interface of the 
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GABAA receptor, that affected benzodiazepine potentiation, had no effect on inverse 
benzodiazepine inhibition (Hanson et al., 2011). Our work supports this hypothesis, as the 
1(K104C)22(D75C) mutant GABAA receptor, which traps the receptor in a ‘positively 
modified’ state, was not inhibited by Ro 15-4513 as much as wildtype receptors (Figure 16C).  
Once DTT is applied, the 1(K104C)22(D75C) receptor is relieved of this ‘positively modified 
state’, and Ro 15-4513 is able to produce inhibition to levels similar to that of wildtype receptors 
(Figure 16C).  Ro 15-4513 produced more inhibition in the 122(D75C) receptor than in the 
wildtype, 1(K104C)22, and 1(K104C)22(D75C) receptors.  Substituting the 2D75 residue 
with a lysine or alanine residue increased the inhibition by Ro 15-4513 even more so than the 
cysteine replacement at that residue (data not shown).  This decrease suggests that the 2D75 
residue may be involved in the conformational change produced by Ro 15-4513 as well as a distinct 
conformational change produced by potentiating benzodiazepines.  
 
After DTT breaks the disulfide bond in 1(K104C)22(D75C) receptors, one might expect 
the receptor to behave similarly to the 1(K104A)22(D75A) receptor.  While the 
1(K104A)22(D75A) receptor exhibited levels of diazepam and flunitrazepam potentiation 
similar to wildtype receptors (Figure 19B), DTT treatment to 1(K104C)22(D75C) receptors did 
not fully restore levels of diazepam potentiation (Figure 16A). One possible explanation for this 
is that DTT breaking the disulfide bond by reducing each mutant cysteine) results in two hydrogen-
bound cysteine residues that would occupy more volume than alanine residues at those positions, 
preventing the conformational change produced by diazepam from occurring.  Another possibility 
is that in the 1(K104C)22(D75C) receptor, the spontaneous reformation of a disulfide bond after 
DTT treatment (Figure 15C and 15D) prevents one from experimentally capturing the maximal 
amount of enhancement produced by diazepam. 
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The 1(K104D)22(D75K) receptor, bearing two charge-reversing substitutions, 
displayed a right-shifted GABA concentration-response curve compared to wildtype receptors 
(Figure 20A). Additionally, the 1(K104D)22(D75K) receptor did not restore GABA, diazepam, 
or Ro 15-4513 sensitivity to wildtype levels (Figure 20B).  This is likely because the 1K104 and 
2D75 residues lie within a pocket of charges, and that modifying these residues is preventing other 
interactions from occurring; i.e., although K104D and D75K substitutions may restore the 
electrostatic interaction between these residues, there are other charged residues near these sites 
that may now interact differently with the reversed charge residues, compared to the original 
wildtype amino acids.  Evidently, the 1K104 - 2D75 interaction is not the only interaction that is 
important for producing the positively modified state of the receptor.  If it were, one would see no 
benzodiazepine potentiation of the receptor after mutating the 1K104 and 2D75 residues. 
 
One might argue that the data obtained from the alanine substitution experiments at 
1K104 and 2D75 do not fit our overall hypothesis that formation of a bond between these two 
residues facilitates benzodiazepine effects at the GABAA receptor.  Perhaps what is happening is 
that during the conformational changes produced by benzodiazepine site agonists at wildtype 
receptors these two charged residues come close enough together to at least partially neutralize 
each others' charges.   This hypothesis is supported by results obtained using the single alanine 
substitutions, which retain single charged residues in each pair, and display weaker effects of 
benzodiazepines than those seen in the double alanine mutant (Figure 19B).  A possible 
explanation may be that the retained charged residue in the single mutants may still be interacting 
with other nearby charged residues (egs. 1K105, 2D148 or 2R197), thus retarding the ability of 
the receptor to adopt the benzodiazepine-activated conformational state.  This would also apply to 
the single cysteine substitutions which also display decreased responses to diazepam and 
flunitrazepam.  In scenarios in which the 1104 and 275 residues are in close proximity (eg., 
 85 
cysteines crosslinked) the receptor has already adopted a benzodiazepine positively-modified state 
and thus adding exogenous benzodiazepine does not have much effect.  In cases where these two 
residues are not initially close together, but are capable of moving closer together, (e.g. the double 
alanine substitutions or the double uncrosslinked cysteines) a greater effect of applied 
benzodiazepine will be seen.  Lastly, in scenarios in which one or the other of these residues is 
constrained in its movement (e.g. single substitutions), benzodiazepine effects would be smaller 
due to the remaining charged residue.   
 
An initial concern was that the receptor mutants were not being incorporated correctly on 
cell surfaces and that oocytes were expressing primarily 12 receptors, not 122 receptors. 
Previous studies used ZnCl2 to test for 2 subunit incorporation, as zinc inhibits 12 receptors to 
a greater extent than 122 GABAA receptors (Draguhn et al., 1990). However, using this test may 
not be the most accurate way to test for  contamination, as even a small fraction of 12 
receptors present may produce a significant inhibitory effect by zinc (Boileau et al., 2002).  
Interestingly, the 12 receptors display an increase in their GABA-evoked currents after DTT 
treatment, but 122 receptor currents are unchanged (Amato et al., 1999).  In our study, we saw 
no change in GABA-evoked currents after DTT treatment in wildtype and mutant receptors, except 
for 1(K104C)22(D75C) receptors, where we actually saw a decrease in GABA-evoked currents 
(Figure 15D).  This, together with the fact that we injected receptors cDNAs in a 11:12:102 
cDNA ratio and we still saw a benzodiazepine effect, engenders confidence that the receptors are 
incorporating wildtype and mutated 2 subunits. 
 
One interesting and clinically-relevant aspect of this study revolves around the additive 
and synergistic properties of GABAA receptor modulators.  Benzodiazepines are often co-abused 
with ethanol, and the two classes of compounds are thought to act additively or synergistically as 
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central nervous system depressants (Dawn Report, 2014).  While ethanol is thought to act at the 
+/- interface in  GABAA receptors, it is not clear if this is necessarily the case in  
receptors (Wallner et al., 2014).  We tested if mutations that affect both GABA and benzodiazepine 
responses also produced changes in ethanol responses.  In the 1(K104C)22(D75C) ‘positively 
modified’ receptor, no changes in ethanol potentiation were observed (Figure 18).  Similarly, the 
charge reversal 1(K104D)22(D75K) receptor exhibits similar ethanol potentiation to that of 
wildtype receptors (data not shown).  These data suggest that the conformational changes in the 
GABAA receptor produced by ethanol are experimentally separable from the conformational 
changes produced by benzodiazepines, and that both can occur simultaneously to further enhance 
receptor function.  This provides a possible molecular mechanism for the synergistic/additive 
effects of benzodiazepines and alcohol.  
 
The neurosteroid allopregnanolone acts as a potent modulator of the GABAA receptor, as 
well as a direct activator at high concentrations. The binding site for this enhancing action is 
thought to be within a cavity formed by transmembrane domains one and four within a single α 
subunit (Akk et al., 2007; Hosie et al., 2006). The 1(K104C)22(D75C) ‘positively modified’ 
receptor and 1(K104D)22(D75K) charge reversal receptor displayed no differences in their 
sensitivities to the potentiating effects of allopregnanolone, compared to wildtype receptors 
(Figure 18). As well as having distinct binding sites, our data suggest that allopregnanolone and 
benzodiazepines produce distinct conformational changes in the GABAA receptor. 
 
In summary, our study suggests that an inter-subunit electrostatic interaction between 
1K104 and 2D75 occurs after benzodiazepine site agonist binding to help stabilize the GABAA 
receptor in a positively modified state. This interaction seems to be more important for classical 
(non-selective between GABAA receptor  subunits) benzodiazepines than non-classical (1 
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selective) compounds.  Additionally, this interaction does not seem to be important for modulators 
of the GABAA receptor acting at non-benzodiazepine sites, suggesting that the 1K104-2D75 
interaction is specific for benzodiazepine site agents. 
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CHAPTER 4: USE OF  PHAGE DISPLAY TO IDENTIFY NOVEL 
COMPOUNDS THAT ACT ON THE GABAA RECEPTOR 
 
4.1 Introduction 
 
Despite animal knockout data suggesting that 2-containing GABAA receptors are a 
therapeutic target for anxiety, no 2-specific GABAA receptor modulator or agonist is currently on 
the market for the treatment of anxiety (Tan et al., 2011). This chapter details how phage display 
can be employed as a technique to find compounds specific for the  receptor. We utilize 
bacteriophage which express a foreign peptide, seven amino acids long, as part of one of its coat 
proteins. The peptide-expressing bacteriophage is ‘panned’ against a target to which the peptide 
could bind, in our case Human Embryonic Kidney-293 (HEK-293) cells expressing the GABAA 
receptor. This technique has advantages over other methods of drug discovery, such as synthetic 
small molecule libraries, since up to 1010
 
unique peptides can be screened at one time, compared 
to ~50,000 small compounds (Inglese et al., 2007, Molek et al., 2011). 
 
This technique has proven to be a successful method of drug discovery, with five drugs 
derived via phage display currently approved by the Food and Drug Administration, such as the 
anti-inflammatory agent Humira®. Many other drugs derived through phage display are currently 
in clinical trials, for indications ranging from cancer to Alzheimer’s disease (Nixon et al., 2014). 
Our lab was the first to use this technique to identify peptide allosteric modulators for a ligand-
gated ion channel, specifically the ionotropic glycine receptor. Further, peptides that act on the 
glycine receptor with subunit selectivity were obtained by panning against unwanted subunit 
compositions (negative selection), before panning against the desired composition (positive 
selection) (Cornelison et al., 2016). This success, coupled with the fact that glycine and GABAA 
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receptors are both members of the same receptor superfamily, increases the likelihood that phage 
display could identify selective peptide modulators of the α2β2γ2 GABAA receptor.  
 
4.2 Methods 
 
All products were purchased from Thermo Fisher Scientific, Waltham, MA, unless 
otherwise noted. 
 
4.2.1 CELL CULTURE 
 
Human Embryonic Kidney (HEK) 293 cells were obtained from American Type Culture 
Collection (Manassas, VA) and stored in liquid nitrogen before use. Prior to beginning phage 
display, cells were thawed and placed in four wells of a polystyrene 12-well tissue culture plate 
(Celltreat, Pepperell, MA), with each well containing 2ml of Dulbecco’s Modified Eagle’s 
Medium (DMEM) (Sigma Aldrich, St. Louis, MO) supplemented with 1% of 100x Glutamax, 10% 
fetal bovine serum, 1% 100x MEM non-essential amino acid solution and 1% penicillin 
streptomycin (5000U/ml penicillin and 5000g/ml streptomycin) (Invitrogen, Carlsbad, CA). 
These cells were incubated at 37ºC and 5% CO2. Every three days the cells were split by aspirating 
the DMEM from the cells and rocking the cells in 2ml of 0.25% Trypsin-EDTA solution for two 
minutes to detach the cells from each well. The detached cells were placed in new wells containing 
fresh DMEM in a 1:5 ratio. After five rounds of cell passaging, and when cells achieved around 
50% confluency, one well containing cells was transfected with 1g 232 receptor DNA (in a 
12:13:102 ratio) using a Polyfect kit (Qiagen, Valenica, CA), while the other three wells were 
left un-transfected. The cells were incubated for 24-36 hours before the phage display panning 
began. 
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4.2.2 PHAGE DISPLAY PANNING 
 
The Ph.D.7 phage display library, consisting of phage expressing heptapeptides, was 
purchased from New England Biolabs (Ipswich, MA). Two wells containing un-transfected HEK-
293 cells were washed three times with phosphate buffered saline supplemented with 1.5% bovine 
serum albumin and 0.1% Tween-20 (PBS+BSA/Tween). 4l of the phage supplied in the kit (2 x 
1011 phage particles) was diluted in 366l of PBS+BSA/Tween and applied to two of the wells 
and rocked at room temperature. After 30 minutes, the unbound phage from one of these wells was 
applied to another un-transfected well, while the unbound phage from the other well was applied 
to the 232 transfected well and rocked at room temperature. After 60 minutes, the unbound 
phage from the second set of wells were removed and the cells in these wells were washed five 
times with PBS+BSA/Tween. To elute the phage, 366l of 0.2M glycine hydrochloride 
(supplemented with 1mg/ml bovine serum albumin) was added to the second set of wells, and the 
cells were rocked for 10 minutes at room temperature. 
 
After 10 minutes, the 366l eluate was neutralized with 55l of 1M tris-hydrochloride (pH 
9), and the solution was removed from the well. 10l of this solution was saved for tittering, while 
the rest of the solution was used for the amplification of phage. 
 
4.2.3 AMPLIFICATION OF PHAGE 
The neutralized eluate from the phage display panning described above was added to a 
flask containing an overnight (A600) Escherichia coli culture in 20ml Luria broth (LB), and 
shaken at 250rpm for 4.5 hours. Cells were then spun down for 10 minutes at 4000g at 4ºC, after 
which 16ml of the supernatant was removed, added to 4ml of Polyethlylene glycol 
8000(20%)/NaCl (PEG/NaCl), and incubated on ice overnight. The next day the 20ml sample was 
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centrifuged at 12,000g for 10 minutes at 4ºC, after which the supernatant was removed and the 
pellet re-suspended in 1ml tris-buffered saline. Following a 10-minute incubation at room 
temperature, the 1ml solution was spun for one minute at 12,000g, and the resulting liquid 
transferred to a clean tube.  PEG/NaCl (1/6 volume) was added to re-precipitate the phage, and the 
mixture incubated on ice for 15 minutes before being spun for 10 minutes at 12,000g. The 
supernatant was then removed, and the phage re-suspended in 200l tris-buffered saline. 10l of 
the amplified phage was saved for titering, and the remainder saved for the subsequent phage 
panning round. 
 
4.2.4 PHAGE TITERING 
Phage titering was essential for two components of the phage display process; first, to 
determine output of phage from each round to observe selection for the target, and second, to 
measure the amplified amount of phage so that the necessary amount could be applied in the 
subsequent panning round.  
 
Prior to phage display titering, LB/IPTG/XGAL (per 1 liter LB: 15g agar, 0.05g isopropyl-
β-D-thiogalactoside (IPTG), 0.04g 5-Bromo-4-chloro-3-indolyl-β-D-galactoside (XGAL), 1mL 
dimethyl formamide) plates were made and stored for up to one week at 4ºC. These plates were 
warmed prior to phage titering. The library cloning vector M13KE has a gene inserted in it coding 
for LacZ, which results in blue phage plaques on LB/IPTG/XGAL plates. Additionally, a 5ml 
culture of Escherichia coli ER2738 was shaken at 250rpm and 37ºC for approximately 5 hours, 
until cells were in mid-log phase, and then 200l of this culture was each placed into 8 Eppendorf 
tubes. 
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24ml of top agar (per 1 liter: 10g Bacto-Tryptone, 5g yeast extract, 5g NaCl, 7g Bacto-
Agar) was melted and aliquoted amongst eight polystyrene tubes. Serial 10-fold dilutions were 
prepared of both the phage eluate (102-105 final dilution) and the amplified phage (108-1011final 
dilution). 10l of each phage dilution was then added to Eppendorf tubes containing 200l of the 
mid-log phase ER2738 cells, vortexed, incubated for two minutes at room temperature, then added 
to a polystyrene tube containing top agar. The top agar-infected cell mixture was immediately 
vortexed and spread onto LB/IPTG/XGAL plates, which were then inverted and incubated 
overnight at 37ºC. Plates that contained 40-100 plaques were counted and multiplied by their 
dilution factor to determine phage output from the previous round and phage input for the 
subsequent round. 
 
4.2.5 PHAGE SEQUENCING 
After three rounds of panning, individual blue plaques were picked and placed in 1ml of 
LB, incubated at 37ºC and shaken at 250rpm overnight. The following day the culture was purified 
using an Invitrogen mini-prep kit according to manufacturer's instructions, and phage DNA was 
sequenced at the University of Texas at Austin sequencing core using a 96III sequencing primer. 
This was repeated after rounds 4 and 5, and output sequences were analyzed for possible consensus 
sequences and traits. Peptides were ordered from and synthesized by Genscript with N-terminal 
acetylation. 
 
4.2.6 PEPTIDE SCREENING WITH 2-ELECTRODE VOLTAGE CLAMP ELECTROPHYSIOLOGY 
Xenopus laevis oocytes were harvested and isolated as described in chapter two, and 
injected with 1.5ng/30nl of either GABAA (, , ; in 1:1:10, 1:1:10 or 1:1 ratios, 
respectively) or glycine ( or  W170S) receptor DNA using a Nanoject II (Drummond 
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Scientific Co., PA). Oocytes expressing GABAA receptor DNA were clamped at -80mV and 
perfused with ND-96 buffer while oocytes expressing glycine receptor DNA were voltage clamped 
at -70mV and perfused with Modified Barth’s Saline, both as described in chapter two. 
 
Once voltage clamped, the receptor agonist EC5 (agonist concentration which produced a 
5% maximal effect) of GABA or glycine receptors was determined and repeated at four minute 
intervals until responses were stable and did not vary by more than 5%. To test for peptide function 
at glycine or GABA receptors, 100M of each peptide was pre-applied for 30 seconds, and then 
co-applied with agonist EC5. This was followed by another agonist EC5 application, to account for 
possible current drift. This experiment was repeated for the GABAA  receptor and the glycine 
1 receptor in the presence of the zinc chelator tricine to control for possible zinc contamination 
in the peptides. The percent modulation produced by peptides was measured as [(IEC5+ peptide/IEC5)-
1] *100. 
 
4.3 Results 
4.3.1 IDENTIFICATION OF PEPTIDES FROM PHAGE DISPLAY PANNING 
Peptides identified from rounds 3-5 were divided into two groups. The first group consisted 
of peptides that appeared in both the control experiment (phage panned twice against un-
transfected HEK-293 cells) and in the  experiment (phage panned once against un-
transfected HEK-293 cells and then again against  transfected HEK-293 cells). 23 peptides 
were identified that fit these criteria (Table 1, left panel). Several traits were identified amongst 
peptides that fell in this group. Serine was the first amino acid in 7/23 of the peptides, and the 
second amino acid in 6/23 peptides. Proline appeared in position 4 of the heptapeptide in 5/23, and 
in position 7 5/23 times. The second group of peptides were peptides that were found in the  
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experimental group (phage panned once against un-transfected HEK-293 cells then against  
transfected HEK-293 cells), but not in the control experiment (phage panned twice against un-
transfected HEK cells). 11 peptides fit into this category (Table 1, right panel). In contrast to group 
1, only 2 of 11 peptides in group 2 had a serine in position 1, and 0 peptides had a serine in position 
2. Proline did appear in position 4 twice in group 2, but only once in position 7. Positively charged 
amino acids in two consecutive positions were observed in 3/23 (13%) heptapeptides in group 1, 
and these occurred between positions 2 and 5 of the peptide. In contrast, 3/11 (27%) of peptides 
from experimental group 2 had two positive amino acids in two consecutive positions, and these 
occurred between position 5 and 7. Two of these peptides from group two had the motif proline-
x-arginine-histidine, where x was either tyrosine or glutamine. This difference in positive amino 
acid residue placement appeared to be the main difference between the two groups of peptides, 
and so the three peptides in group 2 that had two positive amino acids in consecutive positions 
were synthesized and probed electrophysiologically for GABAA receptor activity. 
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Table 1: Sequences of heptapeptides identified through panning against non-transfected 
and  transfected HEK-293 cells.  
Left: 23 peptides identified from panning rounds 3-5 that appeared in both the control group 
(panned twice against non-transfected HEK-293 cells) and the  group (panned against non-
transfected HEK-293 cells followed by  transfected HEK-293 cells). Right: 11 peptides were 
identified that appeared in the  group but that did not appear in the control group. 
Highlighted in red in the right panel is the presence of positively charged amino acids found in 
two consecutive positions within the last three amino acids of the heptapeptide. This was not found 
in any of the peptides identified in the left panel. 
 96 
4.3.2 PEPTIDE HFNPYRH HAS ACTIONS ON GABAA AND GLYCINE RECEPTORS 
100M HFNPYRH had inhibitory actions at ,  and  GABAA receptors, 
with the most inhibition seen at  receptors (Figure 21A, solid black bar). The addition of 
tricine (Figure 21A, solid gray bar) decreased inhibition of  receptors by HFNPYRH to levels 
similar as the  receptor (Figure 21A, dotted bar). Both  receptors with tricine, and 
 receptors, displayed a greater inhibitory effect in response to HFNPYRH than the  
receptor (Figure 21A, hollow bar; see figure legend for statistics). HFNPYRH produced no effect 
on channel function when applied alone, as seen by no change in baseline current during a 30 
second pre-application (Figure 21B) prior to co-application with GABA.  
 
100M HFNPYRH produced slight enhancement of the 1 glycine receptor (Figure 22A, 
solid black bar and Figure 22B, first three currents), but this enhancement was no longer visible 
in the presence of 2.5mM tricine (Figure 22A, hollow bar and Figure 22B, last three currents). 
Additionally, application of peptide HFNPYRH to the zinc-insensitive receptor mutant 1 W170S 
also produced no enhancement of receptor currents; instead a slight reduction in receptor function 
was observed (Figure 22A, solid grey bar). 
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Figure 21. Peptide HFNPYRH decreases GABAA receptor function.  
A. There was a significant effect of mutation/treatment in their responses to HFNPYRH; one way 
ANOVA [F(3,10)=11.67, p<0.01], with a Tukey’s post hoc test showing specific differences. 
100M HFNPYRH decreased  (hollow bar)  (dotted bar) and  (solid black bar) 
GABA function, with  and  receptors showing a greater decrease than  receptors. 
The addition of tricine significantly decreased the amount of inhibition exhibited by  GABAA 
receptors (solid gray bar), but the inhibition was still greater than that observed in  receptors. 
(*, p<0.05; ***, p<0.001). Each bar represents the average from at least three oocytes from at least 
two different frogs, - the standard error of the mean. B. Representative tracing of an  
expressing oocyte’s response to 100M HFNPYRH. The peptide was pre-applied for 30 seconds 
prior to co-application of the peptide with EC5 GABA. 
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Figure 22. Presence of contaminants in peptide HFNPYRH may mask weak inhibitory 
effects at the 1 glycine receptor.  
A. While 100M HFNPYRH appeared to have weak positive modulatory effects at the 1 glycine 
receptor (solid black bar), this effect was reversed in the presence of 2.5mM tricine (hollow bar) 
and in the zinc-insensitive glycine receptor mutant, 1 W170S (solid gray bar). One-way ANOVA 
revealed a significant effect of treatment/mutation [F(2,6)=11.44, p<0.01], with a Tukey’s post-
hoc test showing significant differences in the response of 1 receptors, compared to 1 receptors 
in the presence of tricine and 1 W170S receptors (*,p<0.05; **, p<0.01). Bars represent the 
average of three oocytes from at least two frogs, with error bars representing the standard error of 
the mean. B. Representative tracing of 100M HFNPYRH effects on  1 glycine receptors in the 
absence (left three currents) and presence of 2.5mM tricine (right three currents). HFNPYRH was 
pre-applied for 30 seconds prior to a 30 second co-application with glycine. The positive 
modulatory effect or HFNPYRH disappears in the presence of tricine. 
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4.3.3 ACTIONS OF PEPTIDE WVPQRHQ ON GABAA AND GLYCINE RECEPTORS 
100M WVPQRHQ weakly inhibited  (Figure 23A, hollow bar) and  (Figure 
23A, dotted bar) GABAA receptors to a similar extent.  receptors (Figure 23A, solid black 
bar) showed increased inhibition by WVPQRHQ compared to  and  receptors, 
however the addition of 2.5mM tricine to  receptors reverted inhibitory levels back to that of 
 and  receptors (see Figure 23 legend for statistics). There was no change in baseline 
current when WVPQRHQ was applied alone, and the inhibitory effects of the peptide were only 
seen when the peptide was applied in addition to GABA EC5 (Figure 23B). 
 
100M WVPQRHQ enhanced 1 glycine receptor function by 33.3 ± 1.8 % (Figure 24A, 
solid black bar and Figure 24B, first three tracings) but no modulation of receptor function was 
observed in the presence of tricine (Figure 24A, only error bar visible and Figure 24B, last three 
tracings). 
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Figure 23. Peptide WVPQRH has a weak inhibitory effect on GABAA receptors.  
A. WVPQRH produced significantly different effects in different GABAA receptor conditions: one 
way ANOVA [F(3,11)=5.691, p<0.02], followed by Tukey’s post hoc test. 100M WVPQRH 
similarly inhibited  (hollow bar),  (dotted bar) and  receptors in the presence of 
tricine (solid gray bar) but all of these receptor subtypes differed significantly from  receptors 
in the absence of tricine (solid black bar) (*, p<0.05). Bars represent the mean – the standard error 
of the mean from at least three oocytes from two frogs. B. representative tracing showing the weak 
inhibitory effect of 100M WVPQRHQ on  GABAA receptors when co-applied with GABA 
EC5. 
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Figure 24. Positive modulatory effects of WVPQRHQ on 1 glycine receptors disappear in 
the presence of tricine.  
A. The effect of 100uM WVPQRHQ on 1 glycine receptors in the absence of 2.5 mM tricine 
(solid black bar) is significantly enhanced compared to 1 receptors in the presence of tricine 
(middle column, only error bar visible) and 1 W170S mutant receptors (solid grey bar), one way 
ANOVA [F(2,6)=166.5, p<0.0001] followed by Tukey’s post hoc test (****, p<0.0001). Each bar 
represents the data from three oocytes ± the standard error of the mean. B. Representative tracing 
of 100M WVPQRHQ effects on 1 glycine receptors in the absence (left three currents) and 
presence (right three currents) of 2.5 mM tricine. The presence of tricine eliminated the positive 
modulatory effects of WVPQRHQ seen on 1 glycine receptors when WVPQRHQ was co-applied 
with glycine EC5. 
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4.3.4 ACTIONS OF PEPTIDE TVQHLHR ON GLYCINE AND GABAA RECEPTORS 
100M TVQHLHR weakly inhibited  and  receptors to a similar extent 
(Figure 25A hollow bar and dotted bar, respectively).  receptors (Figure 25A, filled black 
bar) appeared to be inhibited to a greater extent than the  receptors, but not  receptor. 
The presence of 2.5mM tricine reduced the extent of inhibition produced by  receptors (Figure 
25A, filled grey bars) back to levels not significantly different than that produced by  
receptors (see Figure 25 legend for statistics). As with the other peptides, TVQHLHR had to be 
co-applied with EC5 GABA to see effects, with no effect seen with the application of TVQHLHR 
alone, as seen by no change in baseline current during the pre-application of TVQHLHR (Figure 
25B). 
 
Only a slight positive modulatory effect was observed when 100M TVQHLHR was co-
applied with glycine EC5 to the 1 receptor (Figure 26A, filled black bar and Figure 26B, first 
three tracings). This positive modulation was significantly decreased in the presence of 2.5mM 
tricine (Figure 26A, hollow bar and Figure 26B, last three tracings) and in the 1 W170S mutant 
receptor (Figure 26A, solid grey bar).  
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Figure 25. Peptide TVQHLHR negatively modulates GABAA receptors.  
A. The four GABA receptor conditions,  (hollow bar),  (dotted bar),  (solid black 
bar) and  with tricine (solid gray bar) differed significantly in their receptor responses to 
100M TVQHLHR, one way ANOVA [F(3,11)=4.36, p<0.05] with Tukey’s post hoc test (*, 
p<0.05). Each bar represents data from at least three oocytes – the standard error of the mean.  
B. representative tracing of 100M TVQHLHR actions on  GABAA receptors. The co-
application of TVQHLHR with GABA EC5 produces a slight reduction in receptor function, but 
no current is produced by TVQHLHR in the absence of GABA EC5, as seen by the absence of a 
response during a 30 second pre-application of TVQHLHR without GABA EC5. 
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Figure 26. Weak positive modulatory effect of 100M TVQHLHR on 1 glycine receptors 
is absent in the presence of tricine and in the 1 W170S receptor mutant.  
A. 1 glycine receptors (solid black bar), 1 glycine receptors in the presence of 2.5mM tricine 
(hollow bar) and mutant 1 W170S glycine receptors (solid grey bar) differed significantly in their 
responses to 100M TVQHLHR, one way ANOVA [F(2,6)=16.45, p<0.01] with Tukey’s post hoc 
(*, p<0.05; **, p<0.01).Each bar represents data from three oocytes, + or – the standard error of 
the mean. In the case of 1 receptors in the presence of tricine the error is too small to depict. B. 
Representative tracing of the effects of 100M TVQHLHR on 1 glycine receptors in the absence 
(left three currents) and presence (right three currents) of 2.5mM tricine. 100M TVQHLHR 
produces a small potentiation in the  1 glycine receptor when co-applied with glycine EC5, but 
this is eliminated in the presence of tricine. The 30 second pre-application of TVQHLHR prior to 
the co-application with glycine produced no change in baseline current. 
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4.4 Discussion 
In this chapter we demonstrated the use of phage display technology to identify peptides 
capable of changing GABAA receptor function. While previous studies in our lab did not use a 
control screen (panning twice against un-transfected cells), they did employ a negative selection 
process against cells expressing a receptor they did not want to select for before the positive 
selection step against cells expressing the desired target (Tipps et al., 2010; Cornelison et al., 
2016). However, this study found that little selectivity resulted despite including this negative 
selection step, probably due to the similarity between the receptor in the negative selection step 
and receptor in the positive selection step. The GABA 1 and 2 subunits are 81% similar, and 2 
and 3 are 74% similar. Due to the similarity found between the  and  receptors, it 
could be possible that by stringently selecting against  receptors we would eliminate 
peptides that bind both receptor types, but have a greater effect on  over  receptors. 
Additionally, peptide libraries have sequence biases, resulting in certain peptides appearing round 
after round despite no selection for the target occurring (Zade et al., 2017). Hence, we felt it was 
important to include the control experiment, where peptides were panned twice against un-
transfected cells. 
 
In our panning, we found 23 peptides that appeared in both the control and the  
selection experiment, while we found only 11 peptides that appeared solely in the  selection 
experiment (Table 1). Previous phage display experiments in the lab found that the most 
efficacious peptides had specific consensus sequences, and after analyzing traits of our identified 
peptides we noticed the presence of positive amino acids in the tail end of some peptides (Tipps et 
al., 2010; Cornelison et al., 2017). This trait was observed only in peptides found in the  
selective experiment, not in the control experiment. All three peptides tested with two-electrode 
voltage clamp electrophysiology inhibited ,  and  receptors, but to differing 
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extents, with HFNPYRH having the greatest effect. Due to the selection of these peptides based 
on a consensus sequence, it is not surprising that they all acted as negative modulators.  
 
Peptide HFNPYRH displayed selectivity for  GABAA receptors over  GABAA 
receptors, as it inhibited  receptors to a greater extent (Figure 21A dotted bar versus hollow 
bar). To probe if the 2 subunit was necessary for the actions of HFNPYRH, we tested the actions 
of the peptide on  receptors. The  GABAA receptors were still inhibited by HFNPYRH, 
indicating that the 2 subunit is not necessary for this peptide’s actions (Figure 21A, solid black 
bar). The  GABAA receptors are sensitive to low levels of zinc, with zinc acting as an allosteric 
inhibitor of receptor function, while GABAA receptors containing the 2 subunit are only sensitive 
to high levels of zinc. Our lab has previously identified that zinc is a common contaminant in 
labware, buffers, chemicals, and synthetic peptides (Cornelison and Mihic, 2014; Cornelison et 
al., 2016). We therefore wanted to see if the effect of the peptide seen on these receptors was 
possibly due to zinc. Chelating out zinc with tricine reduced the amount that HFNYPYRH 
inhibited  receptors (Figure 21A, filled grey bar) to levels not significantly different than that 
of  receptors. To further test if the peptide had zinc contamination present, we tested peptide 
HFNYPYRH on glycine receptors. Glycine receptors are also sensitive to low levels of zinc, but 
in contrast to  GABAA receptors, they are potentiated by low levels of zinc. 100M HFNPYRH 
produced a slight potentiation in the 1 receptor, but this was reversed upon the addition of tricine 
(Figure 22A and Figure 22B). This indicated the possibility that there was zinc contamination in 
the peptide. Although the addition of tricine resulted in the peptide appearing slightly inhibitory 
when combined with glycine EC5, it is difficult to tell if this is just noise or if the peptide is truly 
having a weak effect. While specific modulators for GABA or glycine receptors exist, it should be 
noted that other modulators, such as ethanol and zinc, are able to act on both receptors. This is not 
surprising given the high amino acid sequence homology between the two receptors. Further 
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evidence of contaminating levels of zinc is peptide HFNPYRH’s actions on the mutant 1 W170S 
receptor. The W170S receptor, in which the glycine receptor 1 subunit tryptophan residue 170 
has been mutated to a serine, is insensitive to the potentiating concentrations of zinc (Cornelison 
et al., 2017). The similar actions of HFNPYRH on the W170S receptors and the  1 glycine 
receptor in the presence of tricine (Figure 22A) further suggests that there are contaminating levels 
of zinc in the peptide. 
 
The second peptide, WVPQRHQ, exhibited no selectivity for  receptors over  
receptors (Figure 23A, hollow and dotted bar). However, the  receptor, lacking a 2 subunit, 
produced significantly more inhibition (Figure 23A, solid black bar). This would suggest that the 
2 was not necessary, or perhaps even hindered the peptide from working effectively. However, in 
the presence of tricine, the level of inhibition by WVPQRHQ was reduced to levels that do not 
differ from  or  receptors, pointing at the possibility of zinc contamination in this 
peptide (Figure 23A, filled gray bar). The possibility of contaminating zinc was further supported 
by the positive modulation of the  1 glycine receptor, which disappeared in the presence of tricine 
and on the W170S receptor (Figure 24A and Figure 24B). 
 
The third peptide, TVQHLHR, also exhibited no selectivity for the  receptor over 
the  (Figure 25A, hollow bar and dotted bar). Both  and  receptors were 
inhibited by TVQHLHR, and although the data appears as though there may be a greater 
enhancement at  receptors than at  receptors, this trend did not result in a significant 
difference. Inhibition of  receptors by TVQHLHR was significantly greater compared to 
inhibition of  receptors, but this was not the case in the presence of tricine (Figure 25A, 
solid black and grey bar). This suggested that TVQHLHR may also have traces of contaminating 
zinc, resulting in a greater apparent inhibition in the absence of tricine. TVQHLHR actions on the 
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 1 glycine receptor and glycine receptor mutants suggested that perhaps a small amount of zinc 
was present (Figure 25B).  
 
The varied effects of the three peptides at the glycine receptor indicates different levels of 
contaminating zinc (Figure 22A, Figure 24A and Figure 26A). However, the level of predicted 
zinc does not correlate with how effectively the peptide inhibits the GABAA receptor. For example, 
peptide WVPQRHQ (Figure 23A, filled black bar) appears to have the most contaminating zinc 
present, as indicated by it producing the most enhancement at 1 glycine receptors; however, it 
has a slightly weaker inhibitory response at  receptors than peptide HFNPYRH (Figure 21A, 
filled black bar). This indicates that the peptides are producing an inhibitory effect, rather than 
contaminating zinc producing an effect.  
 
There was no effect of the peptides when applied alone in the absence of an agonist, 
indicating that the peptides are not acting as direct agonists of the GABAA and glycine receptor. 
However, it is unclear if the three peptides investigated in this study are in fact negative 
modulators, or competitive antagonists. In the case of known inverse agonists, for example Ro 15-
4513, the competition of Ro 15-4513 with a benzodiazepine site antagonist (flumazenil) reveals 
its site of action, the benzodiazepine site. However, these three peptides do not require the 2 
subunit in order to exert their actions, suggesting that they do not act at the benzodiazepine site, as 
benzodiazepines do require the 2 subunit. Therefore, the actions of the peptide would not be 
competed by flumazenil, and at this time the distinction between inverse agonist and competitive 
antagonist cannot be made. 
 
It is important to address the clinical or experimental usefulness of the three peptides 
studied. While one may think that an inverse agonist acting weakly at GABAA receptors would be 
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of no use, and induce anxiety and insomnia rather than alleviate it, the inverse agonist Ro 15-4513 
has proven to be a powerful tool, both experimentally and as a potential therapeutic. Ro 15-4513 
was originally developed as an antidote to alcohol intoxication, as it can block the effects of alcohol 
as well as the effects of benzodiazepines (Bonetti et al., 1988; June and Lewis, 1994). While 
pharmacokinetic and safety concerns prevented it from getting Food and Drug Administration 
approval, it provided a template for which future inverse agonists may have therapeutic use. Ro 
15-4513 has also been useful in other applications, such as in positron emission tomography (Inoue 
et al., 1992; Maeda et al., 2003; Lingford-Hughes et al., 2012; Lingford-Hughes et al., 2016). Thus, 
although the peptides we have identified were opposite in action that what our study aimed to 
achieve, they still have potential to act themselves, or as a template, for future experimental or 
clinical use.  
 
Another concern of this study may be the high concentrations of peptide used to probe 
GABA receptor function. 100M exceeds the concentration that would be of therapeutic use, and 
while lower concentrations were tested (down to 10M), the peptides identified are of low potency. 
However, this is not unusual when compared to other phage display pannings that were completed 
in our lab (Tipps et al., 2010; Cornelison et al., 2016). This low potency might be due to an avidity 
effect, where polyvalent (five identical peptides per phage) display on the bacteriophage may be 
causing a higher apparent affinity compared to what the actual affinity of one peptide to one 
receptor (Lowman, 1997). Additionally, the potency in oocytes might not necessarily be equal to 
what would therapeutically benefit a human. For example, the human blood alcohol concentration 
achieved at the legal driving limit (80 mg/dL) is equal to 17.4mM. However, in most GABAA 
receptors, little effect of ethanol is seen on oocytes until ethanol concentrations exceed 50mM 
(Mihic et al., 1997; Ueno et al., 1999). Yet the culmination of small effects on various receptors is 
thought to contribute to alcohol induced impairment (Wallner et al., 2006). According to this 
 110 
rationale, the peptides that we tested might produce a therapeutic effect at lower concentrations in 
vivo.  
 
This study aimed to find peptides via phage display capable of selectively potentiating the 
 GABAA receptor. A peptide capable acting as a positive modulator at this receptor may 
have therapeutic benefit for the treatment of anxiety. Our study identified three peptides that 
inhibited receptor function, either as a competitive antagonist at the GABA binding site or as an 
inverse agonist at a novel allosteric site While these compounds would produce rather than 
alleviate anxiety, these peptides may be useful in elucidating molecular mechanisms of other 
GABAA receptor acting compounds, or antagonize the effects of other agonists or modulators. 
Moreover, this study acts as a proof-of-principal that phage display technology can be employed 
to find  selective compounds. 
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CHAPTER 5: CONCLUSIONS AND FUTURE DIRECTIONS 
 
Central nervous system disorders involve an imbalance between excitatory and inhibitory 
signaling in the brain, which is in part mediated through ligand-gated ion channels. However, only 
7% of FDA-approved drugs target ligand-gated ion channels, and over half of these drugs were 
approved before 1990 (Santos et al., 2017). This statistic is surprising, given the range of disorders 
in which ligand-gated ion channels have been implicated. This paucity in the recent development 
of drugs targeting ligand-gated ion channels may be a result of the inability to find subunit-
selective compounds, or the move towards more downstream targets in the hope of bypassing off-
target effects. While subunit selectivity may be hard to achieve when comparing agonist binding 
sites between two subtypes of receptors, there may be numerous allosteric binding sites on a 
receptor that do differ between subtypes. Since ligand-gated ion channels are transmembrane 
proteins made up of four (glutamate ion channels) or five (cys-loop channels) subunits, this 
provides multiple binding sites within and between adjacent subunits. Additionally, besides 
providing selectivity, allosteric modulators may also have the property to act as a dimmer switch; 
rather than an agonist (on switch) or antagonist (off switch); an allosteric modulator can tweak 
normal function of the receptor rather than produce a drastic and possible detrimental effect 
(Abdel-Magdid, 2015). This ability to tweak receptor function rather than change it completely 
may be key when targeting ligand-gated ion channels, since they are implicated in so many cellular 
functions.  
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5.1 Endogenous Compounds as Modulators of Ligand-Gated Ion Channel 
Function 
 
Chapter two detailed the ability of ketone bodies to modulate NMDA, GABAA and glycine 
receptor function. My findings demonstrate that endogenous compounds can act as allosteric 
modulators. Other endogenous substances, such as zinc, neurosteroids and polyamines, are also 
capable of modulating ligand-gated ion channel function. These modulators are believed to act at 
different sites, can produce opposing effects at the same receptor (e.g. glycine receptor’s biphasic 
response to zinc), and have opposing functional effects at different receptors (e.g. -
hydroxybutyric acid decreases NMDA receptor function, leading to decreased excitation, but also 
decreases GABA receptor function, leading to decreased inhibition). This demonstrates the 
diversity of possible binding sites for allosteric modulators, but also demonstrates that the actions 
of an allosteric modulator are going to depend on brain region, receptor type, and differences in 
affinity of the modulator for a receptor. In the case of -hydroxybutyric acid, NMDA receptors 
have a higher affinity for the compound than GABAA receptors, suggesting that in a brain region 
expressing both receptors at equal amounts, the net effect of -hydroxybutyric acid would be a 
decrease in excitation. Given the literature surrounding the therapeutic benefits of ketogenesis, 
from preventing epileptic seizures to alleviating alcohol withdrawal symptoms, the actions of -
hydroxybutyric acid on NMDA receptors may be key in producing these effects. Defining the 
allosteric binding sites of ketone body action at NMDA, GABAA and glycine receptor function 
may be key in producing novel compounds that might have the ability to produce the same 
therapeutic benefit as ketogenesis. 
 
The importance of replicating data and ensuring that the necessary control experiments 
were performed is highlighted in chapter two. While we were able to replicate work from several 
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other studies, we were not able to replicate the work of Yang et al. (2007) which detailed positive 
allosteric effects of ketone bodies at GABA and glycine receptors, and no effect of -
hydroxybutyric acid on NMDA receptors. These contradictory results may be a consequence of 
not using adequate controls. Specifically, whenever investigating new compounds that may exert 
actions glycine and NMDA receptors, it is important to control for contaminating zinc in the 
compounds themselves as well as in labware and buffers.  
 
While the benefits of -hydroxybutyric acid in reducing seizures in rodent models has been 
described, it would be interesting to see similar studies conducted for other therapeutic indications. 
Fasting or specific low carbohydrate diets for short periods of time in rodents may not produce 
ketone body levels capable of producing a therapeutic effect, so direct injection of -hydroybutyric 
acid may provide more insight into the clinical potential of ketone bodies/ketone body mimetics. 
Comparing the therapeutic benefit of -hydroxybutyric acid alone and in combination with NMDA 
or GABA receptor antagonists may help decipher if the NMDA and/or GABA receptors are 
mediator(s) of the therapeutic effect. 
 
 
5.2 Understanding the Molecular Mechanism of Benzodiazepine Action 
Despite benzodiazepines being well characterized based on their binding site and their 
separate actions on different GABAA receptor subtypes, a lot remains unknown about how receptor 
binding results in an enhancement of receptor function. Investigating the structural mechanisms 
that underlie allosteric modulation is key for future drug development, and for understanding 
interactions between multiple drugs acting at the same receptor. 
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Other studies have demonstrated that benzodiazepine-site positive modulators induce 
different structural rearrangements in the GABAA receptor compared to negative modulators that 
act on the same site (Boileau and Czajkowski, 1999; Hanson and Czajkowski, 2008). In agreement 
with this, we found that the actions of the benzodiazepine-site inverse agonist Ro 15-453 are not 
impacted by the aspartic acid 75 - lysine 104 electrostatic interaction that we hypothesize is part 
of the structural rearrangement produced by benzodiazepine site positive modulators. While other 
studies suggest that the 1 GABAA receptor selective modulator zolpidem produces a different 
conformational change in the receptor compared to non-selective benzodiazepines, our data 
suggest that they might have some overlap in the conformational rearrangements that they produce.  
 
Interestingly, ethanol and allopregnanolone, believed to act at different sites than the 
benzodiazepine site, were not affected by the crosslinking of 1 lysine 104 and 2 aspartic acid 75. 
Our data suggests that ethanol and allopregnanolone produce different conformational changes in 
the receptor than benzodiazepines, and act in an additive manner to benzodiazepines. This is of 
clinical importance because ethanol and benzodiazepines are often co-abused and produce 
enhanced impairment when taken in combination (Vanover et al., 1998; Chan, 1984).  
 
The electrostatic interaction described in chapter three is likely to be only a part of a wave 
of conformational rearrangements that occur in the receptor after binding either agonists or 
allosteric modulators acting at the benzodiazepine site. Many other electrostatic interactions, and 
non-electrostatic interactions, probably contribute to the enhancement of receptor function, and 
further investigation of these rearrangements will enhance understanding of allosteric modulation 
and the design of future therapeutics. Additionally, our study demonstrated that structural models 
of the GABAA receptor, while not perfect, can provide a useful starting point in untangling the 
conformational wave produced by allosteric modulators. Improving these structural models 
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through further mutagenesis studies will provide a stronger basis for rational drug design at ligand-
gated ion channels. 
 
5.3 Identification of New Allosteric Modulators via Phage Display Technology 
 
In chapter four we utilized genetically modified bacteriophage to pan peptides against a 
desired target, the  receptor. We chose this target due to its therapeutic potential in 
alleviating anxiety without producing sedative effects. Previous work in our lab (Tipps et al., 2010; 
Cornelison et al., 2017) demonstrated that peptides capable of modifying the glycine receptor (a 
target for alcoholism, pain and epilepsy) could be identified using phage display, albeit with low 
affinity and low selectivity between glycine receptor subtypes. However, since the  and 
 receptor have less homology between them than two subtypes of the glycine receptor, we 
felt that it may be possible to achieve selectivity for the  receptor.  
 
Screening of identified peptides with a shared consensus sequence identified three peptides 
that were capable of negatively modifying the receptor. The first peptide, HFNPYRH, was the 
most efficacious and had selectivity for  receptors over  receptors. The other two 
peptides were not as efficacious and had poor selectivity. Applying a chelator and screening the 
peptides against wildtype and mutant glycine receptors ensured that our effects were real and not 
due to contaminating zinc. However, since the peptides we identified were negative modulators of 
the GABAA receptor, they would likely act in an anxiogenic rather than an anxiolytic manner in 
vivo. Additional phage display pannings and electrophysiological screening of other peptides that 
appeared in our initial panning may result in the identification of a selective  positive 
modulator capable of producing anxiolytic effects without sedation. Additionally, including a 
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negative selection step against unwanted targets (e.g. the  receptor) may provide enhanced 
selectivity than what was seen in our study. 
 
Chapter four of this dissertation provides a proof-of-concept for the use of phage display 
to identify allosteric modulators of ligand gated ion channels, for a variety of indications 
mentioned in chapter one. The low potency of peptides identified in this study and previous studies 
should not dissuade one from the use of phage display to identify compounds. Rather, low potency 
peptides that are identified through phage display may provide a starting point to develop a higher 
affinity compound. This could involve the design of new phage display libraries, where variations 
of the initial identified peptide are panned against receptors. 
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